Sattva S. Neelapu, M.D.

Peer-Reviewed Articles

1. Yang H, Arita K, Bowman K, Chihara D, Henderson J, Rost G, Rojas E, Parsons S, Lakra P, Abedin A, Neelapu SS, Strati P, Nastoupil LJ, Fayad L, Iyer SP, Rodriguez A, Hagemeister FB, Malpica L, Lee HJ, Hilton L, Scott DW, Davis RE, Flowers CR, Westin JR, Inghirami G, Vega F, Green MR. A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma. bioRxiv, 2026. e-Pub 2026. PMID: 41648221.
2. Kim K, Shah R, Ayers A, Ahmed S, Claret L, Strati P, Nair R, Nze C, Ramdial J, Torres J, Shpall EJ, Fayad LE, Nastoupil LJ, Westin JR, Flowers CR, Neelapu SS, Chihara D. Clinical trial access after CAR T-cell therapy failure in relapsed/refractory large B-cell lymphoma. Br J Haematol, 2026. e-Pub 2026. PMID: 41521615.
3. Gribben JG, Palomba ML, Limbrick-Oldfield E, Palivela M, Kanters S, Stilla AM, Jacobson CA, Neelapu SS, Nikolajeva O, Yan JH, Ray MD, Ghione P. Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5. Leuk Lymphoma:1-5, 2025. e-Pub 2025. PMID: 41467613.
4. Strati, P, Feng, L, Westin, JR, Nair, R, Fayad, LE, Rodriguez, MA, Chihara, D, Malpica Castillo, LE, Henderson, J, Gallardo, M, Rivera, M, Wang, I, Bolshakova, A, Radko, A, Kurtz, DM, Alig, S, Flowers, CR, Alizadeh, AA, Neelapu, SS. Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40775236.
5. Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson ML, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt JD, Wulff J, Shen RR, Zhang W, Poddar S, Miao H, Nikolajeva O, Jacobson CA. Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. J Clin Oncol 43(33):3573-3577, 2025. e-Pub 2025. PMID: 41100801.
6. Strati, P, Brandt, AC, Lionel, A, Henderson, J, Westin, JR, Adkins, S, Shpall, E, Kebriaei, P, Ramdial, JL, Saini, N, Ahmed, S, Flowers, CR, Neelapu, SS, Hildebrandt, MA. Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy. Journal for immunotherapy of cancer 13(10), 2025. e-Pub 2025. PMID: 41067879.
7. Akkad N, Feng L, Westin JR, Hagemeister FB, Lee HJ, Fayad L, Ahmed S, Nair R, Rodriguez MA, Strati P, Chihara D, Flowers CR, Claret L, Ibanez K, Wang M, Fowler NH, Henderson J, Davis RE, Neelapu SS, Green M, Nastoupil LJ. A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma. Blood Adv 9(17):4396-4404, 2025. e-Pub 2025. PMID: 40517417.
8. Soto F, Ebinama U, Brasher WP, Harding WC, Goizueta A, Walder JR, Ewing A, Shannon VR, Faiz SA, Altan M, Shroff G, Feng L, Neelapu S, Ahmed S, Nastoupil LJ, Sheshadri A. Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Relapsed or Refractory Lymphoma. Clin Lymphoma Myeloma Leuk 25(9):e649-e655, 2025. e-Pub 2025. PMID: 40514309.
9. Locke FL, Le Gall JB, Fisher PW, Neelapu SS. Reply to: Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR Matching. J Clin Oncol 43(25):2834-2835, 2025. e-Pub 2025. PMID: 40549998.
10. Poddar S, Yan J, Tiwari G, Rinchai D, Budka J, Zhang W, Peng W, Salunkhe S, Davis M, Song Q, Beygi S, Miao H, Mattie M, Shen RS, Jacobson CA, Bedognetti D, Filosto S, Neelapu SS. Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma. J Clin Invest 135(16), 2025. e-Pub 2025. PMID: 40536814.
11. Strati P, Feng L, Tyshevich A, Shavronskaya D, Alesse J, English N, Sheehan E, Syzrantsev N, Nesmelov A, Zhuang TZ, Chihara D, Westin JR, Ahmed S, Fayad LE, Henderson J, Dent K, McChesney E, Neelapu SS, Flowers CR. A Phase I Trial of Evorpacept, Lenalidomide and Rituximab for Patients with B-cell Non-Hodgkin Lymphoma. Clin Cancer Res 31(19):4079-4088, 2025. e-Pub 2025. PMID: 40729376.
12. Saha S, Rehman L, Rehman A, Darbaniyan F, Weber DM, Becnel M, Gaballa M, Thomas SK, Lee HC, Chang CC, Arora R, Menges M, Corallo S, Davila ML, Locke FL, Tanner MR, Neelapu SS, Shpall EJ, Flowers CR, Orlowski RZ, Jenq RR, Jain MD, Peterson C, Hansen DK, Saini NY, Patel KK. Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel. Blood Adv 9(14):3429-3440, 2025. e-Pub 2025. PMID: 40198765.
13. Yang H, Zhang W, Ravanmehr V, Cui G, Bowman K, Chen R, Henderson JM, Lockman S, Rojas E, Wilson A, Parsons S, Mechaly A, Regad L, Haouz A, Flowers CR, Neelapu S, Nastoupil L, Davis RE, Deng Q, Rodrigues-Lima F, Green MR. Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement. Blood 146(2):191-205, 2025. e-Pub 2025. PMID: 40090010.
14. Chohan KL, Weber DM, Feng L, Wang LM, Neelapu SS, Olsem J, Johnson RJ, Morales de Partovi C, Orlowski RZ, Thomas SK. Phase I study of pomalidomide in relapsed or refractory Waldenstrom macroglobulinaemia. Br J Haematol 207(1):244-8, 2025. e-Pub 2025. PMID: 40361301.
15. Long JP, Prakash R, Edelkamp P Jr, Knafl M, Lionel AC, Nair R, Ahmed S, Strati P, Castillo LEM, Al-Zaki A, Chien K, Chihara D, Westin J, Khawaja F, Nastoupil LJ, Mulanovich V, Futreal A, Woodman SE, Daver NG, Flowers CR, Neelapu S, Manzano JG, Iyer SP. Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy. JAMA Netw Open 8(4), 2025. e-Pub 2025. PMID: 40193078.
16. Jain H, Karulkar A, Kalra D, Ravikumar S, Shah S, Firfiray A, Pendhari J, Jaiswal AK, Khan A, Sundharam M, Vaibhaw A, Saroha A, Rajyopadhye S, Basu M, Asija S, Chowdhury A, Beher R, Banik A, Dwivedi A, Purwar S, Narula G, Banavali S, Jain N, Highfill SL, Stroncek D, Fry T, Melinkeri S, Wilson L, Agarwal N, Aribandi A, Boyella PK, Shah NN, Neelapu SS, Sengar M, Purwar R. Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study. Lancet Haematol 12(4):e282-e293, 2025. e-Pub 2025. PMID: 40090352.
17. Gopal AK, Armand P, Neelapu SS, Bartlett NL, Spurgeon SE, Kuruvilla J, Savage KJ, Leonard JP, Gelb AB, Ahmed N, Dong S, Bathena SP, Suryawanshi R, Wu QJ, Wang S, Gladstone DE. Nivolumab plus relatlimab in patients with relapsed or progressed B-cell malignancies in RELATIVITY-022. Blood Adv, 2025. e-Pub 2025. PMID: 40030000.
18. Locke FL, Munoz JL, Tees MT, Lekakis LJ, de Vos S, Nath R, Stevens DA, Malik SA, Shouse GP, Hamadani M, Oluwole OO, Perales MA, Miklos DB, Fisher PW, Feng A, Navale L, Le Gall JB, Neelapu SS. Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies. J Clin Oncol 43(14):101200JCO2401933, 2025. e-Pub 2025. PMID: 39946666.
19. Chavez JC, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani C, Lin Y, Riedell PA, Kekre N, de Vos S, Wullf J, Williams CM, Winters J, Kloos IM Dr, Xu H, Neelapu SS. Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12). Blood 145(20):2303-2311, 2025. e-Pub 2025. PMID: 39938019.
20. Chihara D, Steiner RE, Nair R, Feng L, Ahmed S, Strati P, Malpica Castillo LE, Griffith D, Mathew SA, Montinez W, Masand G, Samaniego F, Rodriguez MA, Hagemeister FB, Fayad LE, Iyer SP, Nastoupil LJ, Neelapu SS, Flowers CR, Westin JR. Phase II trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas. Blood Adv 9(7):1485-1491, 2025. e-Pub 2025. PMID: 39908461.
21. Walder J, Soto-Lanza F, Feng L, Ahmed S, Neelapu S, Ayers A, Grosu HB, Faiz SA, Nastoupil L, Sheshadri A. Role of Pulmonary Function Tests to Predict Complications After Chimeric Antigen Receptor T-Cell Therapy. Clin Lymphoma Myeloma Leuk 25(7):520-526, 2025. e-Pub 2025. PMID: 40000355.
22. Manzar, G, Pinnix, CC, Dudzinski, SO, Marqueen, KE, Cha, E, Nasr, L, Yoder, A, Rooney, MK, Strati, P, Ahmed, S, Nze, CC, Nair, R, Fayad, LE, Wang, L, Nastoupil, L, Westin, JR, Flowers, CR, Neelapu, SS, Gunther, J, Dabaja, BS, Wu, SY, Fang, PQ. Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas. Frontiers in immunology 16, 2025. e-Pub 2025. PMID: 39958356.
23. Manzar GS, Pinnix CC, Dudzinski SO, Marqueen KE, Cha EE, Nasr LF, Yoder AK, Rooney MK, Strati P, Ahmed S, Nze C, Nair R, Fayad LE, Wang M, Nastoupil LJ, Westin JR, Flowers CR, Neelapu SS, Gunther JR, Dabaja BS, Wu SY, Fang PQ. Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas. Front Immunol 16:1517348, 2025. e-Pub 2025. PMID: 39958356.
24. Wu SY, Fang PQ, Fetooh A, Manzar GS, Corrigan KL, Schrank BR, Nasr L, Chihara D, Castillo LEM, Nair R, Steiner RE, Jain P, Neelapu SS, Strati P, Nastoupil LJ, Dabaja BS, Pinnix CC, Gunther JR. Ultra-Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the Lung. Adv Radiat Oncol 9(12):101648, 2024. e-Pub 2024. PMID: 39524525.
25. Fang P, Noticewala SS, Wu SY, Gunther JR, Ludmir EB, Medeiros LJ, Strati P, Nair R, Nze C, Nastoupil LJ, Ahmed S, Castillo LM, Fayad L, Westin J, Neelapu S, Flowers C, Huen A, Iyer SP, Dabaja B, Pinnix CC. Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?. Adv Radiat Oncol 9(12):101650, 2024. e-Pub 2024. PMID: 39553398.
26. Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Kersten MJ, Zheng Y, Zhang T, Nater J, Shen R, Miao H, Kim JJ, Miklos DB. Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma. Transplant Cell Ther 30(11):1065-1079, 2024. e-Pub 2024. PMID: 39187161.
27. Prasad R, Rehman A, Rehman L, Darbaniyan F, Blumenberg V, Schubert ML, Mor U, Zamir E, Schmidt S, Hayase T, Chia-Chi C, McDaniel LK, Flores I, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Wang ML, Jain P, Nastoupil LJ, Westin JR, Arora R, Turner JG, Khawaja F, Wu R, Dennison JB, Menges M, Hidalgo-Vargas M, Reid KM, Davila ML, Dreger P, Korell F, Schmitt A, Tanner MR, Champlin RE, Flowers CR, Shpall EJ, Hanash S, Neelapu SS, Schmitt M, Subklewe M, Fahrmann J, Stein-Thoeringer C, Elinav E, Jain MD, Hayase E, Jenq RR, Saini NY. Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. Blood 145(8):823-839, 2024. e-Pub 2024. PMID: 39441941.
28. Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Dorritie KA, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Ulrickson M, Westin J, Chavez JC, Patel D, Jacobs MT, Bansal R, Bennani NN, Patel VG, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Lunning M, Dahiya S. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol 42(30):3581-3592, 2024. e-Pub 2024. PMID: 39094076.
29. Manzar GS, Wu SY, Dudzinski SO, Cha EE, Yoder AK, Corrigan KL, Nasr LF, Sallard G, Ahmed S, Fayad LE, Chihara D, Nair R, Westin JR, Daher M, Neelapu SS, Nastoupil LJ, Gunther JR, Pinnix CC, Dabaja BS, Strati P, Fang PQ. Characterization of Lymphopenia and Correlating the Risk of Cytopenias With Dose and Bone Marrow Volume Irradiated in Aggressive B Cell Lymphoma Patients Bridged With Radiation Therapy for Chimeric Antigen Receptor-T Cell Therapy. Int J Radiat Oncol Biol Phys 121(4):1011-1025, 2024. e-Pub 2024. PMID: 39303997.
30. Pinnix CC, Dabaja BS, Gunther JR, Fang PQ, Wu SY, Nastoupil LJ, Strati P, Nair R, Ahmed S, Steiner R, Westin J, Neelapu S, Rodriguez MA, Lee HJ, Wang M, Flowers C, Feng L, Esmaeli B. Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial. JAMA Oncol 10(9):1195-1203, 2024. e-Pub 2024. PMID: 38990564.
31. Szymura SJ, Wang L, Zhang T, Cha SC, Song J, Dong Z, Anderson A, Oh E, Lee V, Wang Z, Parshottam S, Rao S, Olsem JB, Crumpton BN, Lee HC, Manasanch EE, Neelapu S, Kwak LW, Thomas SK. Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial. Nat Commun 15(1):6874, 2024. e-Pub 2024. PMID: 39128904.
32. Gurumurthi A, Chin CK, Feng L, Fowler NH, Strati P, Hagemeister FB, Fayad LE, Westin JR, Obi C, Arafat J, Nair R, Steiner RE, Neelapu SS, Flowers CR, Nastoupil LJ. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial. EClinicalMedicine 74:102747, 2024. e-Pub 2024. PMID: 39161543.
33. Rezvan A, Romain G, Fathi M, Heeke D, Martinez-Paniagua M, An X, Bandey IN, Montalvo MJ, Adolacion JRT, Saeedi A, Sadeghi F, Fousek K, Puebla-Osorio N, Cooper LJN, Bernatchez C, Singh H, Ahmed N, Mattie M, Bot A, Neelapu S, Varadarajan N. Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling. Nat Cancer 5(7):1010-1023, 2024. e-Pub 2024. PMID: 38750245.
34. Gunther JR, Xu J, Bhutani MS, Strati P, Fang PQ, Wu SY, Dabaja BS, Dong W, Bhosale PR, Flowers CR, Nair R, Malpica Castillo L, Fayad L, Iyer SP, Parmer S, Wang M, Lee HJ, Samaniego F, Westin J, Ahmed S, Nze CC, Jain P, Neelapu SS, Rodriguez MA, Chihara D, Nastoupil LJ, Pinnix CC. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial. Lancet Haematol 11(7):e521-e529, 2024. e-Pub 2024. PMID: 38843856.
35. Lionel AC, Neelapu SS. CAR T-cell expansion: harmful or helpful?. Blood Adv 8(12):3311-3313, 2024. e-Pub 2024. PMID: 38916899.
36. Jallouk, AP, Kui, N, Sun, R, Westin, JR, Steiner, RE, Nair, R, Nastoupil, L, Fayad, LE, Zaki, AA, Hawkins, MC, Adkins, S, Noorani, M, Das, K, Henderson, J, Shpall, E, Kebriaei, P, Ramdial, JL, Flowers, CR, Neelapu, SS, Ahmed, S, Strati, P. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica 109(5):1460-1468, 2024. e-Pub 2024. PMID: 38031807.
37. Jallouk, AP, Kui, N, Sun, R, Westin, JR, Steiner, RE, Nair, R, Nastoupil, L, Fayad, LE, Zaki, AA, Hawkins, MC, Adkins, S, Noorani, M, Das, K, Henderson, J, Shpall, E, Kebriaei, P, Ramdial, JL, Flowers, CR, Neelapu, SS, Ahmed, S, Strati, P. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica 109(5):1460-1468, 2024. e-Pub 2024. PMID: 38031807.
38. Lionel AC, Gurumurthi A, Fetooh A, Eldaya R, Ahmed S, Iyer SP, Nastoupil LJ, Westin J, Nair R, Fayad L, Malpica L, Tummala S, Flowers C, Neelapu SS, Wang ML, Jain P. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement. Leuk Lymphoma 65(5):669-673, 2024. e-Pub 2024. PMID: 38248629.
39. Lunning MA, Wang HL, Hu ZH, Locke FL, Siddiqi T, Jacobson CA, Ahmed S, Miklos DB, Lin Y, Hill BT, Ghobadi A, Neelapu SS, Westin J, Dieyi C, Field P, Miao H, Shahani SA, Patel A, Spooner C, Fu C, Muramoto D, Xu H, Pasquini MC. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Am J Hematol 99(5):880-889, 2024. e-Pub 2024. PMID: 38504387.
40. Kumaresan PR, Wurster S, Bavisi K, da Silva TA, Hauser P, Kinnitt J, Albert ND, Bharadwaj U, Neelapu S, Kontoyiannis DP. A novel lentiviral vector-based approach to generate chimeric antigen receptor T cells targeting Aspergillus fumigatus. mBio 15(4):e0341323, 2024. e-Pub 2024. PMID: 38415653.
41. Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer 130(6):876-885, 2024. e-Pub 2024. PMID: 37985359.
42. Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos D, Neelapu SS, Locke FL, Ghobadi A. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood Adv 8(4):1042-1050, 2024. e-Pub 2024. PMID: 38051550.
43. Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood 143(6):496-506, 2024. e-Pub 2024. PMID: 37879047.
44. Manzar GS, Cha EE, Corrigan KL, Yoder AK, Schrank BR, Nasr LF, Chihara D, Castillo LM, Nair R, Jain P, Neelapu SS, Rodriguez MA, Strati P, Nastoupil LJ, Gunther JR, Dabaja BS, Pinnix CC, Wu SY, Fang PQ. Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs. Front Oncol 14:1447020, 2024. e-Pub 2024. PMID: 39324011.
45. Chu, F, Cao, J, Liu, J, Yang, H, Davis, TJ, Kuang, SQ, Cheng, X, Zhang, Z, Karri, S, Vien, LT, Bover, L, Sun, R, Vega Vazquez, F, Green, M, Davis, RE, Neelapu, SS. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. Journal for immunotherapy of cancer 11(11), 2023. e-Pub 2023. PMID: 38007239.
46. Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Rep Med 4(8):101158, 2023. e-Pub 2023. PMID: 37586321.
47. Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN. Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). Transplant Cell Ther 29(7):438.e1-438.e16, 2023. e-Pub 2023. PMID: 36906275.
48. Strati P, Pasvolsky O, Feng L, Xu G, Tewari SO, Varghese J, Ow K, Santiago M, Al Zaki A, Jallouk A, Neelapu SS, Kebriaei P, Shpall EJ, Ahmed S. ASCT vs CART for Patients with Relapsed LBCL in PR: Role of TMTV. Blood Adv 7(11):2586-2589, 2023. e-Pub 2023. PMID: 36745104.
49. Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, Thomas SK, Hao D, Chu Y, Weber DM, Lin P, Lutter-Berka Z, Berrios Nolasco DA, Huang M, Bansal H, Song X, Zhang J, Futreal A, Moreno Rueda LY, Symer DE, Green MR, Rojas Hernandez CM, Kroll M, Afshar-Khargan V, Ndacayisaba LJ, Kuhn P, Neelapu SS, Orlowski RZ, Wang L, Manasanch EE. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell 41(6):1032-1047.e4, 2023. e-Pub 2023. PMID: 37311413.
50. Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Singareeka Raghavendra A, Yang-Kolodji G, Chu F, Neelapu SS, Marchese A, Hanash S, Zimmermann J, Arteaga CL, Tripathy D. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Res 25(1):62, 2023. e-Pub 2023. PMID: 37280713.
51. Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Padmanabhan Iyer S, Horowitz SB, Nastoupil LJ, Nair R, Hassan A, Daoud T, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell Lymphoma. Blood Adv. e-Pub 2023. PMID: 37389847.
52. Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy AH, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Bot AA, Shen RR, Dong J, Singh K, Miao H, Kim JJ, Zheng Y, Locke FL. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1). Blood 141(19):2307-2315, 2023. e-Pub 2023. PMID: 36821768.
53. Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, Dahiya S, Beitinjaneh AM, Jacobs MT, Mcguirk JP, Vose JM, Goy A, Andreadis C, Hill BT, Dorritie KA, Oluwole OO, Deol A, Paludo J, Shah B, Wang T, Banerjee R, Miklos DB, Rapoport AP, Lekakis L, Ghobadi A, Neelapu SS, Lin Y, Wang ML, Jain MD. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. J Clin Oncol 41(14):JCO2201797, 2023. e-Pub 2023. PMID: 36753699.
54. Wang XS, Srour SA, Mendoza T, Whisenant M, Subbiah I, Gonzalez E, Kamal M, Shen SE, Cleeland C, Kebriaei P, Rezvani K, Neelapu S, Ahmed S, Shpall E. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy. Br J Haematol 201(4):738-746, 2023. e-Pub 2023. PMID: 36733986.
55. Cherng HJ, Alig SK, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister F, Craig AFM, Macaulay CW, Rodriguez MA, Lee HJ, McDonnell TJ, Flowers CR, Vega F, Green MR, Feng L, Kurtz DM, Alizadeh AA, Davis RE, Westin JR. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv 7(7):1137-1145, 2023. e-Pub 2023. PMID: 36375046.
56. Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Shpall EJ, Neelapu SS, Nieto Y, Strati P. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica 108(4):1163-1167, 2023. e-Pub 2023. PMID: 36384251.
57. Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med 29(4):906-916, 2023. e-Pub 2023. PMID: 36914893.
58. Steiner RE, Parra ER, Vega F, Feng L, Westin JR, Neelapu SS, Strati P, Green MR, Flowers CR, Solis LM, Wistuba II, Ahmed S, Nair R, Hagemeister FB, Noorani M, Marques-Piubelli ML. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma. Exp Hematol Oncol 12(1):32, 2023. e-Pub 2023. PMID: 36941707.
59. Wang Z, Zhang T, Anderson A, Lee V, Szymura S, Dong Z, Kuang B, Oh E, Liu J, Neelapu SS, Kwak L, Cha SC. Immortalized B Cells Transfected with mRNA of Antigen Fused to MITD (IBMAM): An Effective Tool for Antigen-Specific T-Cell Expansion and TCR Validation. Biomedicines 11(3), 2023. e-Pub 2023. PMID: 36979775.
60. Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Raghavendra AS, Yang-Kolodji G, Chu F, Neelapu SS, Hanash S, Zimmermann J, Arteaga CL, Tripathy D. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Res Sq, 2023. e-Pub 2023. PMID: 36824840.
61. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol 41(4):JCO2200597, 2023. e-Pub 2023. PMID: 35952327.
62. Palomba ML, Ghione P, Patel AR, Nahas M, Beygi S, Hatswell AJ, Kanters S, Limbrick-Oldfield EH, Wade SW, Ray MD, Owen J, Neelapu SS, Gribben J, Radford J, Bobillo S. A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Expert Rev Anticancer Ther 23(2):199-206, 2023. e-Pub 2023. PMID: 36723678.
63. Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2023. PMID: 36068929.
64. Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, Jain P, Wang M, Green M, Westin J, Blumenberg V, Davila M, Champlin R, Shpall EJ, Kebriaei P, Flowers CR, Jain M, Jenq R, Stein-Thoeringer CK, Subklewe M, Neelapu SS, Hanash S. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med 3(11):100720, 2022. e-Pub 2022. PMID: 36384092.
65. Strati P, Jallouk AP, Sun R, Choi J, Das K, Cherng HJ, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Steiner RE, Huff CD, Yu Y, Mistry H, Pulsifer B, Noorani M, Saini N, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Hildebrandt MAT, Neelapu SS. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. Leukemia 36(11):2669-2677, 2022. e-Pub 2022. PMID: 36127509.
66. Pemmaraju N, Wilson NR, Senapati J, Economides MP, Guzman ML, Neelapu SS, Kazemimood R, Davis RE, Jain N, Khoury JD, Sugita M, Cai T, Smith J, Frattini MG, Garton A, Roboz G, Konopleva M. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Leuk Res 121:106928, 2022. e-Pub 2022. PMID: 35963025.
67. Jacobs MT, Jain MD, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan PM, Oluwole OO, McGuirk J, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Ghobadi A, Locke FL. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clin Lymphoma Myeloma Leuk 22(10):753-759, 2022. e-Pub 2022. PMID: 35780055.
68. Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov 3(5):428-443, 2022. e-Pub 2022. PMID: 35687817.
69. Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov 3(5):385-393, 2022. e-Pub 2022. PMID: 35533245.
70. Romain G, Strati P, Rezvan A, Fathi M, Bandey IN, Adolacion JRT, Heeke D, Liadi I, Marques-Piubelli ML, Solis LM, Mahendra A, Vega F, Cooper LJ, Singh H, Mattie M, Bot A, Neelapu SS, Varadarajan N. Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses. J Clin Invest 132(17), 2022. e-Pub 2022. PMID: 35881486.
71. Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, Chang EC, Neelapu SS, Miklos DB, Jacobson CA, Lekakis LJ, Lin Y, Ghobadi A, Kim JJ, Chou J, Plaks V, Wang Z, Xue A, Mattie M, Rossi JM, Bot A, Galon J. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med 28(9):1872-1882, 2022. e-Pub 2022. PMID: 36038629.
72. Ghione P, Palomba ML, Patel AR, Bobillo S, Deighton K, Jacobson CA, Nahas M, Hatswell AJ, Jung AS, Kanters S, Snider JT, Neelapu SS, Ribeiro MT, Brookhart MA, Ghesquieres H, Radford J, Gribben JG. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood 140(8):851-860, 2022. e-Pub 2022. PMID: 35679476.
73. Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. Blood 140(5):504-515, 2022. e-Pub 2022. PMID: 35512184.
74. Steiner RE, Banchs J, Koutroumpakis E, Becnel M, Gutierrez C, Strati P, Pinnix CC, Feng L, Rondon G, Claussen C, Palaskas N, Karimzad K, Ahmed S, Neelapu SS, Shpall E, Wang M, Vega F, Westin J, Nastoupil LJ, Deswal A. Cardiovascular events in patients treated with chimeric antigen receptor t-cell therapy for aggressive B-cell lymphoma. Haematologica 107(7):1555-1566, 2022. e-Pub 2022. PMID: 34758610.
75. Marques-Piubelli ML, Parra ER, Feng L, Soto LS, Gallardo M, Gouni S, Samaniego F, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Fowler NH, Flowers CR, Wistuba II, Nastoupil LJ, Vega F, Strati P. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Adv 6(11):3286-3293, 2022. e-Pub 2022. PMID: 35359004.
76. Gouni S, Rosenthal AC, Crombie JL, Ip A, Kamdar MK, Hess B, Feng L, Watson G, Ayers A, Neelapu SS, Khurana A, Lin Y, Iqbal M, Merryman RW, Strati P. A Multicenter Retrospective Study of Polatuzumab Vedotin in Patients with Large B-cell Lymphoma After CAR T-cell Therapy. Blood Adv 6(9):2757-2762, 2022. e-Pub 2022. PMID: 35240681.
77. Al Zaki A, Feng L, Watson G, Ahmed SA, Mistry H, Nastoupil LJ, Hawkins M, Nair R, Iyer SP, Lee HJ, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Westin JR, Strati P. Day 30 SUVmax Predicts Progression in Lymphoma Patients Achieving PR/SD After CAR T-cell Therapy. Blood Adv 6(9):2867-2871, 2022. e-Pub 2022. PMID: 35015825.
78. Cai T, Gouble A, Black KL, Skwarska A, Naqvi AS, Taylor D, Zhao M, Yuan Q, Sugita M, Zhang Q, Galetto R, Filipe S, Cavazos A, Han L, Kuruvilla V, Ma H, Weng C, Liu CG, Liu X, Konoplev S, Gu J, Tang G, Su X, Al-Atrash G, Ciurea S, Neelapu SS, Lane AA, Kantarjian H, Guzman ML, Pemmaraju N, Smith J, Thomas-Tikhonenko A, Konopleva M. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun 13(1):2228, 2022. e-Pub 2022. PMID: 35484100.
79. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
80. Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med 28(4):735-742, 2022. e-Pub 2022. PMID: 35314842.
81. Ma MCJ, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, Moore D, Akhter A, Hartert K, Jain N, Showell J, Ghosh S, Street L, Davidson M, Carey C, Tobin J, Perumal D, Vose JM, Lunning MA, Sohani AR, Chen BJ, Buckley S, Nastoupil LJ, Davis RE, Westin JR, Fowler NH, Parekh S, Gandhi M, Neelapu S, Stewart D, Bhalla K, Iqbal J, Greiner T, Rodig SJ, Mansoor A, Green MR. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica 107(3):690-701, 2022. e-Pub 2022. PMID: 33792219.
82. Nastoupil LJ, Chin CK, Westin JR, Fowler NH, Samaniego F, Cheng X, Ma MCJ, Wang Z, Chu F, Dsouza L, Obi C, Mims J, Feng L, Zhou S, Green M, Davis RE, Neelapu SS. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Adv 6(4):1143-1151, 2022. e-Pub 2022. PMID: 35015819.
83. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22(2):85-96, 2022. e-Pub 2022. PMID: 34601571.
84. Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 23(1):91-103, 2022. e-Pub 2022. PMID: 34895487.
85. Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 63(1):1-10, 2022. e-Pub 2022. PMID: 34435552.
86. Ragoonanan D, Bhar S, Mohan G, Beltramo F, Khazal SJ, Hurley C, Andersen C, Margossian S, Neelapu SS, Shpall E, Gutierrez C, Tewari P, Shoberu B, Talleur A, McCall D, Nunez C, Cuglievan B, Tambaro FP, Petropoulos D, Abdel-Azim H, Mahadeo KM. A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy. Front Oncol 12:1022901, 2022. e-Pub 2022. PMID: 36353531.
87. Singh S, Roszik J, Saini N, Singh VK, Bavisi K, Wang Z, Vien LT, Yang Z, Kundu S, Davis RE, Bover L, Diab A, Neelapu SS, Overwijk WW, Rai K, Singh M. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade. Front Immunol 13:794684, 2022. e-Pub 2022. PMID: 35720386.
88. Wang XS, Srour SA, Whisenant M, Subbiah IM, Chen TH, Ponce D, Gonzalez AG, Kamal M, Mendoza T, Cleland CS, Kebriaei P, Neelapu SS, Rezvani K, Ahmed S, Shpall E. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies. Transplant Cell Ther 27(11):930.e1-930.e10, 2021. e-Pub 2021. PMID: 34265479.
89. Whisenant MS, Srour SA, Williams LA, Subbiah I, Griffin D, Ponce D, Kebriaei P, Neelapu SS, Shpall E, Ahmed S, Wang XS. The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. Semin Oncol Nurs:151216. e-Pub 2021. PMID: 34629213.
90. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste E, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) versus salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv 5(20):4149-4155, 2021. e-Pub 2021. PMID: 34478487.
91. Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Chen Y, Horowitz S, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 106(10):2667-2672, 2021. e-Pub 2021. PMID: 32732355.
92. Al Feghali KA, Fang P, Gule-Monroe M, Milgrom S, Khoury JD, Gunther JR, Sheu T, Nair R, Ahmed S, Steiner R, Strati P, Shpall EJ, Nieto YL, Hosing C, Nastoupil LJ, Westin JR, Neelapu SS, Fowler N, Flowers C, Pinnix CC, Dabaja BS. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma 62(10):1-8, 2021. e-Pub 2021. PMID: 33942701.
93. Handley G, Khawaja F, Kondapi DS, Lee HJ, Kaufman GP, Neelapu SS, Fayad LE, Tummala S, Chi L, Strati P, Mulanovich VE. Human Herpesvirus-6 Myelitis after Chimeric Antigen Receptor T-cell Therapy. Int J Infect Dis. e-Pub 2021. PMID: 34600133.
94. Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, Wang Z, Kuang SQ, Chu F, Davis RE, Vega F, Bashir Z, Jacobson CA, Locke FL, Reagan PM, Rodig SJ, Lekakis LJ, Flinn IW, Miklos DB, Bot A, Neelapu SS. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood 138(12):1081-1085, 2021. e-Pub 2021. PMID: 34041526.
95. Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, Fowler NH, Westin J, Lee HJ, Wang M, Hagemeister F, Cecil ARL, Dow J, Haque K, Silva FA, Whale A, Lensun L, Bone EA, McElwaine-Johnn H, Beer PA. Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma. Leuk Lymphoma:1-11. e-Pub 2021. PMID: 34365878.
96. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. e-Pub 2021. PMID: 34264268.
97. Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma 62(6):1-12, 2021. e-Pub 2021. PMID: 33480830.
98. Mueller-Schoell A, Puebla-Osorio N, Michelet R, Green MR, Künkele A, Huisinga W, Strati P, Chasen B, Neelapu SS, Yee C, Kloft C. Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers (Basel) 13(11), 2021. e-Pub 2021. PMID: 34205020.
99. Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Blood 137(23):3272-3276, 2021. e-Pub 2021. PMID: 33534891.
100. Mamlouk O, Nair R, Iyer SP, Edwards A, Neelapu SS, Steiner RE, Adkins SA, Hawkins M, Saini N, Devashish K, Strati P, Mandayam S, Ahmed S. Safety and Efficacy of CAR T-Cell Therapy in Kidney Transplant Recipients. Blood 137(18):2558-2562, 2021. e-Pub 2021. PMID: 33512386.
101. Nair R, Drillet G, Lhomme F, Le Bras A, Michel L, Rossi J, Sherman M, Xue A, Kerber A, Jittapiromsak N, Chi L, Tummala S, Neelapu SS, Houot R. Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. Haematologica 106(5):1504-1506, 2021. e-Pub 2021. PMID: 32732365.
102. Singh S, Xiao Z, Bavisi K, Roszik J, Melendez BD, Wang Z, Cantwell MJ, Davis RE, Lizee G, Hwu P, Neelapu SS, Overwijk WW, Singh M. IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol 206(8):1966-1975, 2021. e-Pub 2021. PMID: 33722878.
103. Spiegel JY, Dahiya S, Jain MD, Tamaresis J, Nastoupil LJ, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose JM, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill BT, Miklos DB. Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. Blood 137(13):1832-1835, 2021. e-Pub 2021. PMID: 33156925.
104. Fang P, Gunther JR, Pinnix CC, Dong W, Strati P, Nastoupil LJ, Steiner RE, Ahmed S, Damron EP, Fowler N, Nair R, Westin JR, Neelapu S, Ha CS, Dabaja BS. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys 109(5):1414-1420, 2021. e-Pub 2021. PMID: 33309978.
105. Strati P, Jain P, Johnson RJ, Forbes S, Feng L, Samaniego F, Rodriguez MA, Fayad LE, Hagemeister F, Westin J, Wang M, Neelapu SS, Nastoupil LJ, Fowler NH. Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma. Blood 137(8):1124-1129, 2021. e-Pub 2021. PMID: 32932518.
106. Sarkar A, Stellrecht CM, Vangapandu HV, Ayres M, Kaipparettu BA, Park JH, Balakrishnan K, Burks JK, Pandita TK, Hittelman WN, Neelapu SS, Gandhi V. Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma. Haematologica 106(2):495-512, 2021. e-Pub 2021. PMID: 32029507.
107. Samaniego F, McLaughlin P, Neelapu SS, Feng L, Fanale M, Nastoupil L, Rodriguez MA, Pro B, Taylor E, Hagemeister FB, Fowler N. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leuk Lymphoma 62(1):1-10, 2021. e-Pub 2021. PMID: 32924687.
108. Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33335028.
109. Chin CK, Lim KJ, Lewis K, Jain P, Qing Y, Feng L, Cheah CY, Seymour JF, Ritchie D, Burbury K, Tam CS, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Samaniego F, Flowers CR, Nastoupil LJ, Dickinson MJ. Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study. Br J Haematol 191(5):806-815, 2020. e-Pub 2020. PMID: 33065767.
110. Chin CK, Rodriguez MA, Qing Y, Feng L, Samaniego F, Jain P, Noorani M, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Flowers CR, Nastoupil LJ. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. Leuk Lymphoma 61(12):1-5, 2020. e-Pub 2020. PMID: 32628087.
111. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26(12):1878-1887, 2020. e-Pub 2020. PMID: 33020644.
112. Neelapu SS, Adkins S, Ansell SM, Brody J, Cairo MS, Friedberg JW, Kline JP, Levy R, Porter DL, van Besien K, Werner M, Bishop MR. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33361336.
113. Furqan F, Watson G, Samaniego F, Fayad LE, Kanagal-Shamanna R, Morrison MW, Thompson PA, Steiner RE, Chi L, Dabaja B, Pinnix CC, Neelapu SS, Nastoupil LJ, Strati P. Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. Leuk Lymphoma 61(12):1-5, 2020. e-Pub 2020. PMID: 32650677.
114. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res 26(21):5579-5587, 2020. e-Pub 2020. PMID: 33055173.
115. Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, Oluwole OO, Reagan PM, Lekakis LJ, Lin Y, Sherman M, Better M, Go WY, Wiezorek JS, Xue A, Bot A. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4(19):4898-4911, 2020. e-Pub 2020. PMID: 33035333.
116. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol 38(27):JCO1902104, 2020. e-Pub 2020. PMID: 32401634.
117. Pinnix CC, Gunther JR, Fang P, Bankston ME, Milgrom SA, Boyce D, Lee HJ, Nair R, Steiner R, Strati P, Ahmed S, Iyer SP, Westin J, Parmar S, Rodriguez MA, Nastoupil L, Neelapu S, Flowers C, Dabaja BS. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Netw Open 3(9):e2013935, 2020. e-Pub 2020. PMID: 32990738.
118. Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4(16):3943-3951, 2020. e-Pub 2020. PMID: 32822484.
119. Gutierrez C, Brown ART, Herr MM, Kadri SS, Hill B, Rajendram P, Duggal A, Turtle CJ, Patel K, Lin Y, May HP, Gallo de Moraes A, Maus MV, Frigault MJ, Brudno JN, Athale J, Shah NN, Kochenderfer JN, Dharshan A, Beitinjaneh A, Arias AS, McEvoy C, Mead E, Stephens RS, Nates JL, Neelapu SS, Pastores SM. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. J Crit Care 58:58-64, 2020. e-Pub 2020. PMID: 32361219.
120. Glober G, Gunther J, Fang P, Milgrom S, Korivi BR, Jensen CT, Wagner-Bartak NA, Ahmed S, Lee HJ, Nair R, Steiner R, Parmar S, Iyer S, Westin J, Fayad L, Rodriguez MA, Neelapu S, Nastoupil L, Flowers CR, Dabaja BS, Pinnix CC. Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. Clin Lymphoma Myeloma Leuk 20(8):533-541, 2020. e-Pub 2020. PMID: 32291233.
121. Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv 4(13):2871-2883, 2020. e-Pub 2020. PMID: 32589728.
122. Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, Horowitz SB, Brown ART, Do B, Rodriguez MA, Nair R, Shpall EJ, Green MR, Neelapu SS, Westin JR. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv 4(13):3123-3127, 2020. e-Pub 2020. PMID: 32645136.
123. Kohorst MA, Nunez CA, Tewari P, Petropoulos D, Mahadeo KM, Neelapu SS, Shpall EJ, Khazal S. Primary mediastinal large B-cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy. Br J Haematol 190(2):e114-e117, 2020. e-Pub 2020. PMID: 32469086.
124. Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica 105(7):1907-1913, 2020. e-Pub 2020. PMID: 31601688.
125. Gunther JR, Pinnix CC, Glober GR, Christopherson KM, Fang P, Lee HJ, Ahmed S, Steiner RE, Nair R, Strati P, Neelapu SS, Nastoupil LJ, Dabaja BS. Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?. EJHaem 1(1):272-276, 2020. e-Pub 2020. PMID: 32864660.
126. Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, Bartlett NL, Braunschweig I, Jiang Y, Kim JJ, Zheng L, Rossi JM, Locke FL. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 135(23):2106-2109, 2020. e-Pub 2020. PMID: 32181801.
127. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma 61(6):1-8, 2020. e-Pub 2020. PMID: 31971032.
128. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
129. Fowler NH, Nastoupil L, De Vos S, Knapp M, Flinn IW, Chen R, Advani RH, Bhatia S, Martin P, Mena R, Davis RE, Neelapu SS, Eckert K, Ping J, Co M, Beaupre DM, Neuenburg JK, Palomba ML. The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. Br J Haematol 189(4):650-660, 2020. e-Pub 2020. PMID: 32180219.
130. Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, Logan T, Lossos IS, Urba W, Salles G, Ramchandren R, Jacobson C, Godwin J, Carpio C, Lathers D, Liu Y, Neely J, Suryawanshi S, Koguchi Y, Levy R. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol 95(5):510-520, 2020. e-Pub 2020. PMID: 32052473.
131. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4(6):1038-1050, 2020. e-Pub 2020. PMID: 32191807.
132. Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, Ghosh S, Mottok A, Nastoupil L, Neelapu SS, Weigert O, Inghirami G, Baselga J, Younes A, Yee C, Dogan A, Scheinberg DA, Roeder RG, Melnick AM, Green MR. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discov 10(3):440-459, 2020. e-Pub 2020. PMID: 31915197.
133. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. e-Pub 2020. PMID: 32023374.
134. Locke FL, Go WY, Neelapu SS. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review. JAMA Oncol 6(2):1-10, 2020. e-Pub 2020. PMID: 31697310.
135. Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma 61(2):1-9, 2020. e-Pub 2020. PMID: 31533521.
136. Overman M, Javle M, Davis RE, Vats P, Kumar-Sinha C, Xiao L, Mettu NB, Parra ER, Benson AB, Lopez CD, Munugalavadla V, Patel P, Tao L, Neelapu S, Maitra A. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32114502.
137. Gunther JR, Park C, Dabaja BS, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Garg N, Amini B, Steiner R, Nair R, Strati P, Westin JR, Lee HJ, Fowler N, Nastoupil L, Neelapu SS, Pinnix CC. Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leuk Lymphoma 61(1):171-175, 2020. e-Pub 2020. PMID: 31373240.
138. Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Ruiz Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Front Immunol 11:590494, 2020. e-Pub 2020. PMID: 33552049.
139. Andraos TY, Ayoub Z, Nastoupil LJ, Milgrom SA, Pinnix CC, Ng SP, Gunther JR, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Dabaja BS. Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. Leuk Lymphoma 60(13):3258-3265, 2019. e-Pub 2019. PMID: 31234671.
140. Chu F, Li HS, Liu X, Cao J, Ma W, Ma Y, Weng J, Zhu Z, Cheng X, Wang Z, Liu J, Jiang ZY, Luong AU, Peng W, Wang J, Balakrishnan K, Yee C, Dong C, Davis RE, Watowich SS, Neelapu SS. CXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity. Leukemia 33(11):2640-2653, 2019. e-Pub 2019. PMID: 31028278.
141. Ayoub Z, Andraos T, Milgrom SA, Pinnix CC, Dabaja BS, Ng SP, Gunther JR, Khoury JD, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Nastoupil LJ. Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. Leuk Lymphoma 60(10):1-9, 2019. e-Pub 2019. PMID: 30942648.
142. Abu-Sbeih H, Tang T, Ali FS, Luo W, Neelapu SS, Westin JR, Okhuysen PC, Foo WC, Curry JL, Richards DM, Ge PS, Wang Y. Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. Am J Clin Oncol 42(10):789-796, 2019. e-Pub 2019. PMID: 31478934.
143. Manasanch EE, Han G, Mathur R, Qing Y, Zhang Z, Lee H, Weber DM, Amini B, Berkova Z, Eterovic K, Zhang S, Zhang J, Song X, Mao X, Morgan M, Feng L, Baladandayuthapani V, Futreal A, Wang L, Neelapu SS, Orlowski RZ. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv 3(15):2400-2408, 2019. e-Pub 2019. PMID: 31405950.
144. Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Hartmann E, Kridel R, Smedby KE, Juliusson G, Rosenquist R, Gascoyne RD, Rosenwald A, Giancotti F, Neelapu SS, Westin J, Vose JM, Lunning MA, Greiner T, Rodig S, Iqbal J, Alizadeh AA, Davis RE, Bhalla K, Green MR. Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Sci Transl Med 11(497), 2019. e-Pub 2019. PMID: 31217338.
145. Pinnix CC, Gunther JR, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Amini B, Neelapu S, Lee HJ, Westin J, Fowler N, Nastoupil L, Dabaja B. Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa- Associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys 104(2):447-455, 2019. e-Pub 2019. PMID: 30769175.
146. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol 185(5):874-882, 2019. e-Pub 2019. PMID: 30919940.
147. Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-Cell Therapy in Patients with B-Cell Lymphoma and Chronic Hepatitis B or C Virus Infection. Blood 133(26):2800-2802, 2019. e-Pub 2019. PMID: 31101626.
148. Andraos T, Ayoub Z, Nastoupil L, Pinnix C, Milgrom S, Gunther J, Ng SP, Fowler N, Neelapu S, Samaniego F, Dabaja B. Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes. Clin Lymphoma Myeloma Leuk 19(6):381-389, 2019. e-Pub 2019. PMID: 30935940.
149. Mallepally N, Abu-Sbeih H, Ahmed O, Chen E, Shafi MA, Neelapu SS, Wang Y. Clinical Features of Rituximab-associated Gastrointestinal Toxicities. Am J Clin Oncol 42(6):539-545, 2019. e-Pub 2019. PMID: 31136371.
150. Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol 94(6):E150-E153, 2019. e-Pub 2019. PMID: 30785215.
151. Kim ST, Bittar M, Kim HJ, Neelapu SS, Zurita AJ, Nurieva R, Suarez-Almazor ME. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. J Immunother Cancer 7(1):126, 2019. e-Pub 2019. PMID: 31088575.
152. Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv 3(9):1356-1367, 2019. e-Pub 2019. PMID: 31036721.
153. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?. Ann Hematol 98(5):1169-1176, 2019. e-Pub 2019. PMID: 30617643.
154. Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. Br J Haematol 185(4):670-678, 2019. e-Pub 2019. PMID: 30820940.
155. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 41(5):1546, 2019. e-Pub 2019. PMID: 30990235.
156. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol 185(2):334-338, 2019. e-Pub 2019. PMID: 29978452.
157. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 20(1):31-42, 2019. e-Pub 2019. PMID: 30518502.
158. Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk 19(1):e51-e61, 2019. e-Pub 2019. PMID: 30360985.
159. Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol 183(4):578-587, 2018. e-Pub 2018. PMID: 30175400.
160. Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol 3(4):639-646, 2018. e-Pub 2018. PMID: 30370365.
161. Pinnix CC, Cella L, Andraos TY, Ayoub Z, Milgrom SA, Gunther J, Thosani S, Wogan C, Conson M, D'Avino V, Oki Y, Fanale M, Lee HJ, Neelapu S, Fayad L, Hagemeister F, Rodriguez MA, Nastoupil LJ, Nieto Y, Qiao W, Pacelli R, Dabaja B. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. Int J Radiat Oncol Biol Phys 101(3):530-540, 2018. e-Pub 2018. PMID: 29681481.
162. Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, Fayad LE, Neelapu SS, Cheah CY. Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget 9(48):28897-28902, 2018. e-Pub 2018. PMID: 29988979.
163. Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer 124(12):2561-2569, 2018. e-Pub 2018. PMID: 29723393.
164. Pinnix CC, Ng AK, Dabaja BS, Milgrom SA, Gunther JR, Fuller CD, Smith GL, Abou Yehia Z, Qiao W, Wogan CF, Akhtari M, Mawlawi O, Medeiros LJ, Chuang HH, Martin-Doyle W, Armand P, LaCasce AS, Oki Y, Fanale M, Westin J, Neelapu S, Nastoupil L. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv 2(11):1334-1343, 2018. e-Pub 2018. PMID: 29895624.
165. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Ju Lee H, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 40(6):1335, 2018. e-Pub 2018. PMID: 29851218.
166. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys 100(5):1146-1154, 2018. e-Pub 2018. PMID: 29452771.
167. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2018. PMID: 28792260.
168. Qin H, Wei G, Sakamaki I, Dong Z, Cheng WA, Smith DL, Wen F, Sun H, Kim K, Cha S, Bover L, Neelapu SS, Kwak LW. Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell MalignanciesIn Vivo. Clin Cancer Res 24(5):1114-1123, 2018. e-Pub 2018. PMID: 29180606.
169. Thomas SK, Cha SC, Smith DL, Kim KH, Parshottam SR, Rao S, Popescu M, Lee VY, Neelapu SS, Kwak LW. Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer 18(1):187, 2018. e-Pub 2018. PMID: 29439670.
170. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk 18(1):e103-e108, 2018. e-Pub 2018. PMID: 29196178.
171. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One 13(3):e0191461, 2018. e-Pub 2018. PMID: 29538376.
172. Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma 58(12):1-12, 2017. e-Pub 2017. PMID: 28482717.
173. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377(26):2531-2544, 2017. e-Pub 2017. PMID: 29226797.
174. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol 179(3):503-506, 2017. e-Pub 2017. PMID: 27378601.
175. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800-1808, 2017. e-Pub 2017. PMID: 28774879.
176. Haymaker C, Yang Y, Wang J, Zou Q, Sahoo A, Alekseev A, Singh D, Ritthipichai K, Hailemichael Y, Hoang ON, Qin H, Schluns KS, Wang T, Overwijk WW, Sun SC, Bernatchez C, Kwak LW, Neelapu SS, Nurieva R. Absence of Grail promotes CD8(+) T cell anti-tumour activity. Nat Commun 8(1):239, 2017. e-Pub 2017. PMID: 28798332.
177. Pinnix CC, Andraos TY, Dabaja B, Milgrom S, Smith G, Chihara D, Ng A, Fayad LE, Oki Y, Neelapu S, Westin J, Rodriguez MA, Nastoupil LJ. Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions. Adv Radiat Oncol 2(3):370-380, 2017. e-Pub 2017. PMID: 29114605.
178. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. Blood 130(4):472-477, 2017. e-Pub 2017. PMID: 28522441.
179. Takahashi K, Wang F, Kantarjian H, Song X, Patel K, Neelapu S, Gumbs C, Little L, Tippen S, Thornton R, DiNardo CD, Ravandi F, Bueso-Ramos C, Zhang J, Wu X, Garcia-Manero G, Futreal PA. Copy number alterations detected as clonal hematopoiesis of indeterminate potential. Blood Adv 1(15):1031-1036, 2017. e-Pub 2017. PMID: 29296745.
180. Huang XJ, Liu K, Ritchie D, Andersson B, Lu J, Hou J, Burguera AF, Wang J, Yeoh A, Yan C, Zhou D, Tan D, Kim DW, Wu D, Shpall E, Kornblau S, Neelapu S, Hongeng S, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Hagemeister F, Westin J, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Orlowski RZ, Chim CS, Mulligan S, Sanz M, Ozawa K, Parmar S, Issaragrisil S. Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget 8(25):41620-41630, 2017. e-Pub 2017. PMID: 28404929.
181. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 39(6):1095-1100, 2017. e-Pub 2017. PMID: 28370694.
182. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol 177(2):263-270, 2017. e-Pub 2017. PMID: 28340281.
183. Yu L, Tu M, Cortes J, Xu-Monette ZY, Miranda RN, Zhang J, Orlowski RZ, Neelapu S, Boddu PC, Akosile MA, Uldrick TS, Yarchoan R, Medeiros LJ, Li Y, Fajgenbaum DC, Young KH. Clinical and pathological characteristics of HIV- and HHV8- negative Castleman disease. Blood 129(12):1658-1668, 2017. e-Pub 2017. PMID: 28100459.
184. Shank BR, Do B, Sevin A, Chen SE, Neelapu SS, Horowitz SB. Chimeric Antigen Receptor T Cells in Hematologic Malignancies. Pharmacotherapy 37(3):334-345, 2017. e-Pub 2017. PMID: 28079265.
185. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol 176(5):750-758, 2017. e-Pub 2017. PMID: 27983760.
186. Damiani E, Puebla-Osorio N, Lege BM, Liu J, Neelapu SS, Ullrich SE. Platelet activating factor-induced expression of p21 is correlated with histone acetylation. Sci Rep 7:41959, 2017. e-Pub 2017. PMID: 28157211.
187. Mathur R, Sehgal L, Havranek O, Köhrer S, Khashab T, Jain N, Burger JA, Neelapu SS, Davis RE, Samaniego F. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica 102(2):373-380, 2017. e-Pub 2017. PMID: 27742770.
188. Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther 25(1):285-295, 2017. e-Pub 2017. PMID: 28129122.
189. Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo CD, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol 18(1):100-111, 2017. e-Pub 2017. PMID: 27923552.
190. Mannino RG, Santiago-Miranda AN, Pradhan P, Qiu Y, Mejias JC, Neelapu SS, Roy K, Lam WA. 3D microvascular model recapitulates the diffuse large B-cell lymphoma tumor microenvironment in vitro. Lab Chip 17(3):407-414, 2017. e-Pub 2017. PMID: 28054086.
191. Yang Q, Chen LS, Ha MJ, Do KA, Neelapu SS, Gandhi V. Idelalisib impacts cell growth through inhibiting translation regulatory mechanisms in mantle cell lymphoma. Clin Cancer Res 23(1):181-192, 2017. e-Pub 2017. PMID: 27342398.
192. Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Br J Haematol 175(3):531-533, 2016. e-Pub 2016. PMID: 26683805.
193. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 122(20):3145-3151, 2016. e-Pub 2016. PMID: 27351173.
194. Weng J, Moriarty KE, Baio FE, Chu F, Kim SD, He J, Jie Z, Xie X, Ma W, Qian J, Zhang L, Yang J, Yi Q, Neelapu SS, Kwak LW. IL-15 enhances the antitumor effect of human antigen-specific CD8(+) T cells by cellular senescence delay. Oncoimmunology, 2016. e-Pub 2016.
195. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol 175(2):290-299, 2016. e-Pub 2016. PMID: 27448187.
196. Li HS, Liu C, Xiao Y, Chu F, Liang X, Peng W, Hu J, Neelapu SS, Sun SC, Hwu P, Watowich SS. Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells. Sci Signal 9(447):ra94, 2016. e-Pub 2016. PMID: 27678219.
197. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol 2(8):1065-9, 2016. e-Pub 2016. PMID: 27227654.
198. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol 27(7):1317-23, 2016. e-Pub 2016. PMID: 27091808.
199. Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant 22(7):1333-7, 2016. e-Pub 2016. PMID: 27064056.
200. Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano JF, Neelapu SS, Kelly KR, Copeland AR, Akins A, Clancy MS, Gong L, Wang J, Ma A, Viner JL, Oki Y. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol 17(5):622-31, 2016. e-Pub 2016. PMID: 27049457.
201. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, (*equal contribution) *FN. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 27(5):895-901, 2016. e-Pub 2016. PMID: 26802151.
202. Zhang H, Chen Z, Neelapu SS, Romaguera J, McCarty N. Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment. Oncotarget 7(12):14350-65, 2016. e-Pub 2016. PMID: 26885608.
203. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal 9(415):ra17, 2016. e-Pub 2016. PMID: 26884599.
204. Sarkar A, Balakrishnan K, Chen J, Patel V, Neelapu SS, McMurray JS, Gandhi V. Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. Oncotarget 7(3):3461-76, 2016. e-Pub 2016. PMID: 26658105.
205. Weng J, Baio FE, Moriarty KE, Torikai H, Wang H, Liu Z, Maiti SN, Gwak D, Popescu MS, Cha SC, Cooper LJ, Neelapu SS, Kwak LW. Targeting B-cell malignancies through human B-cell receptor specific CD4 T cells. Oncoimmunology 5(11):e1232220, 2016. e-Pub 2016. PMID: 27999743.
206. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol 171(5):726-35, 2015. e-Pub 2015. PMID: 26358140.
207. Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol 171(4):463-70, 2015. e-Pub 2015. PMID: 26213141.
208. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509-16, 2015. e-Pub 2015. PMID: 26260306.
209. Fowler NH, Nastoupil LJ, Hagemeister FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica 100(11):e454-7, 2015. e-Pub 2015. PMID: 26250576.
210. Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, Wallace M, Klinger M, Carlton V, Kong K, Faham M, Younes A. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol 169(5):689-93, 2015. e-Pub 2015. PMID: 25818067.
211. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol 169(6):814-23, 2015. e-Pub 2015. PMID: 25828695.
212. Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood 125(21):3357-9, 2015. e-Pub 2015. PMID: 25999447.
213. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by (18)fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 92(1):113-21, 2015. e-Pub 2015. PMID: 25863759.
214. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 2015. e-Pub 2015. PMID: 25445468.
215. Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS, Samaniego F. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol 8(1):63, 2015. e-Pub 2015. PMID: 26048374.
216. Sehgal L, Mathur R, Braun FK, Wise JF, Berkova Z, Neelapu S, Kwak LW, Samaniego F. FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. Leukemia 28(12):2376-87, 2014. e-Pub 2014. PMID: 24811343.
217. Voo KS, Foglietta M, Percivalle E, Chu F, Nattamai D, Harline M, Lee ST, Bover L, Lin HY, Baladandayuthapani V, Delgado D, Luong A, Davis RE, Kwak LW, Liu YJ, Neelapu SS. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer 135(12):2834-46, 2014. e-Pub 2014. PMID: 24771328.
218. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 2014. e-Pub 2014. PMID: 25439689.
219. Samaniego F, Berkova Z, Romaguera JE, Fowler N, Fanale MA, Pro B, Shah JJ, McLaughlin P, Sehgal L, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW. (90) Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol 167(2):207-13, 2014. e-Pub 2014. PMID: 25040450.
220. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 2014. e-Pub 2014. PMID: 24943107.
221. Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintás-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoo M, Kimura S, Andreeff M, Kojima K. Induction of p53-mediated transcription and apoptosis by Exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci 105(7):795-801, 2014. e-Pub 2014. PMID: 24766216.
222. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 2014. e-Pub 2014. PMID: 24386943.
223. Liu X, Chen X, Zhong B, Wang A, Wang X, Chu F, Nurieva RI, Yan X, Chen P, van der Flier LG, Nakatsukasa H, Neelapu SS, Chen W, Clevers H, Tian Q, Qi H, Wei L, Dong C. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature 507(7493):513-8, 2014. e-Pub 2014. PMID: 24463518.
224. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 2014. e-Pub 2014. PMID: 24332512.
225. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res 19(24):6882-90, 2013. e-Pub 2013. PMID: 24097867.
226. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 2013. e-Pub 2013. PMID: 24117234.
227. Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell Non-Hodgkin lymphoma. Br J Haematol 163(1):123-6, 2013. e-Pub 2013. PMID: 23795711.
228. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27(9):1902-9, 2013. e-Pub 2013. PMID: 23545991.
229. Wang L, Qian J, Lu Y, Li H, Bao H, He D, Liu Z, Zheng Y, He J, Li Y, Neelapu S, Yang J, Kwak LW, Yi Q, Cai Z. Immune evasion evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica 98(9):1458-66, 2013. e-Pub 2013. PMID: 23508008.
230. Yang Q, Chen LS, Neelapu SS, Gandhi V. Combination of Pim Kinase Inhibitor SGI-1776 and Bendamustine in B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S355-62, 2013. e-Pub 2013. PMID: 24290221.
231. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, Baladandayuthapani V, Luong A, Vega F, Fowler N, Dong C, Davis RE, Neelapu SS. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol 190(12):6681-93, 2013. e-Pub 2013. PMID: 23686488.
232. Cha SC, Qin H, Kannan S, Rawal S, Watkins LS, Baio FE, Wu W, Ong J, Wei J, Kwak B, Kim S, Popescu MS, Paick DS, Kim K, Luong A, Davis RE, Schroeder HW, Kwak LW, Neelapu SS. Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen. J Immunol 190(9):4887-98, 2013. e-Pub 2013. PMID: 23536634.
233. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 2013. e-Pub 2013. PMID: 23276888.
234. Foglietta M, * Neelapu SS, contribution) *(, Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR. Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Bone Marrow Transplant 48(2):269-77, 2013. e-Pub 2013. PMID: 22773122.
235. Chen Z, Pittman EF, Romaguera J, Fayad L, Wang M, Neelapu SS, McLaughlin P, Kwak L, McCarty N. Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma. PLoS One 8(8):e69126, 2013. e-Pub 2013. PMID: 23936317.
236. Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J. Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes. J Clin Oncol 30(33):4161-7, 2012. e-Pub 2012. PMID: 22965964.
237. Yang Q, Chen LS, Neelapu SS, Miranda RN, Medeiros LJ, Gandhi V. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood 120(17):3491-500, 2012. e-Pub 2012. PMID: 22955922.
238. Weng J, Rawal S, Chu F, Park HJ, Sharma R, Delgado DA, Fayad L, Fanale M, Romaguera J, Luong A, Kwak LW, Neelapu SS. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood 120(8):1613-23, 2012. e-Pub 2012. PMID: 22645177.
239. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI. Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. J Clin Oncol 30(22):2776-82, 2012. e-Pub 2012. PMID: 22753910.
240. Buglio D, Palakurthi S, Byth K, Vega F, Toader D, Saeh J, Neelapu SS, Younes A. Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood 120(2):347-55, 2012. e-Pub 2012. PMID: 22649101.
241. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716-23, 2012. e-Pub 2012. PMID: 22677155.
242. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(26):6373-8, 2012. e-Pub 2012. PMID: 22586182.
243. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 2012. e-Pub 2012. PMID: 22371887.
244. Wang W, Corrigan-Cummins M, Hudson J, Maric I, Simakova O, Neelapu SS, Kwak LW, Janik JE, Gause B, Jaffe ES, Calvo KR. MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica 97(4):586-94, 2012. e-Pub 2012. PMID: 22102710.
245. Qian J, Zheng Y, Zheng C, Wang L, Qin H, Hong S, Li H, Lu Y, He J, Yang J, Neelapu S, Kwak LW, Hou J, Yi Q. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood 119(1):161-9, 2012. e-Pub 2012. PMID: 22049519.
246. Westin JR, Gibbs A, Mills KR, Neelapu SS. Hodgkin lymphoma untreated for six years presenting with tracheoesophageal fistula. Case Report Med 2012:457908, 2012. e-Pub 2012. PMID: 22811723.
247. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, Li Z, Drouin M, Patterson T, Ward MR, Paulus JK, Ji Y, Medeiros LJ, Martell RE. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 12(13):1222-8, 2011. e-Pub 2011. PMID: 22033282.
248. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F, Vega F. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 30(49):1-13, 2011. e-Pub 2011. PMID: 21625222.
249. Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 118(15):4140-9, 2011. e-Pub 2011. PMID: 21844567.
250. Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, Molldrem JJ, Wang M, Neelapu SS, Kwak LW. Targeting human B-cell malignancies through Ig light chain specific cytotoxic T lymphocytes. Clin Cancer Res 17(18):5945-52, 2011. e-Pub 2011. PMID: 21813633.
251. Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, Rawal S, Wang YH, Lim H, Reynolds JM, Zhou XH, Fan HM, Liu ZM, Neelapu SS, Dong C. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med 17(8):983-8, 2011. e-Pub 2011. PMID: 21785430.
252. Schuster SJ, * Neelapu SS, * (*equal contribution) Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 29(20):2787-94, 2011. e-Pub 2011. PMID: 21632504.
253. Jamshed S, Fowler DH, Neelapu SS, Dean RM, Steinberg SM, Odom J, Bryant K, Hakim F, Bishop MR. EPOCH-F: a novel salvage regimen for multiple myeloma prior to reduced-intensity allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 46(5):676-81, 2011. e-Pub 2011. PMID: 20661232.
254. Park HJ, Qin H, Cha SC, Sharma R, Chung Y, Schluns KS, Neelapu SS, Overwijk WW, Hwu P, Kwak LW. Induction of TLR4-dependent CD8+ T cell immunity by murine ß-defensin2 fusion protein vaccines. Vaccine 29(18):3476-82, 2011. e-Pub 2011. PMID: 21382485.
255. Weng J, Neelapu SS, Woo AF, Kwak LW. Identification of Human Idiotype-Specific T Cells in Lymphoma and Myeloma. Curr Top Microbiol Immunol 344:193-210, 2011. e-Pub 2011. PMID: 20549471.
256. Dennison JB, Shanmugam M, Ayres ML, Qian J, Krett NL, Medeiros LJ, Neelapu SS, Rosen ST, Gandhi V. 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. Blood 116(25):5622-30, 2010. e-Pub 2010. PMID: 20844237.
257. Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, Caraway N, Neelapu SS, Kwak LW, Simmons PJ, McCarty N. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res 5(3):212-25, 2010. e-Pub 2010. PMID: 20851072.
258. Qin H, Cha SC, Neelapu SS, Liu C, Wang YH, Wei J, Qin XF, Liu YJ, Kwak LW. Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines. Vaccine 28(50):7970-8, 2010. e-Pub 2010. PMID: 20937320.
259. Qin H, Cha SC, Neelapu SS, Lou Y, Wei J, Liu YJ, Kwak LW. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Blood 114(19):4142-9, 2009. e-Pub 2009. PMID: 19749091.
260. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(31):5213-8, 2009. e-Pub 2009. PMID: 19770379.
261. Gloghini A, Buglio D, Khaskhely NM, Georgakis G, Orlowski RZ, Neelapu SS, Carbone A, Younes A. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol 147(4):515-25, 2009. e-Pub 2009. PMID: 19775297.
262. Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 27(18):3036-43, 2009. e-Pub 2009. PMID: 19414675.
263. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Fayad L, Wayne Saville M, Kwak LW. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 20(4):709-14, 2009. e-Pub 2009. PMID: 19150940.
264. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12):5530-6, 2008. e-Pub 2008. PMID: 18411419.
265. Lee ST, Liu S, Radvanyi L, Sukhumalchandra P, Molldrem JJ, Wieder ED, Hwu P, Liu YJ, Kwak LW, Lizée G, Neelapu SS. A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. J Immunol Methods 331(1-2):13-26, 2008. e-Pub 2008. PMID: 17959194.
266. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112(4):831-6, 2008. e-Pub 2008. PMID: 18085611.
267. Zhu K, Qin H, Cha SC, Neelapu SS, Overwijk W, Lizee GA, Abbruzzese JL, Hwu P, Radvanyi L, Kwak LW, Chang DZ. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine 25(46):7955-61, 2007. e-Pub 2007. PMID: 17933439.
268. Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol 138(4):502-5, 2007. e-Pub 2007. PMID: 17608763.
269. Popescu MC, Robb RJ, Batenjany MM, Boni LT, Neville ME, Pennington RW, Neelapu SS, Kwak LW. A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. Blood 109(12):5407-10, 2007. e-Pub 2007. PMID: 17351111.
270. Neelapu SS, Gause BL, Harvey L, Lee ST, Frye AR, Horton J, Robb RJ, Popescu MC, Kwak LW. A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood 109(12):5160-3, 2007. e-Pub 2007. PMID: 17339422.
271. O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher TA, Gulley JL, Schlom J, Nussenblatt R, Albert P, Davis TA, Lowy I, Petrus M, Waldmann TA, Janik JE. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 13(3):958-64, 2007. e-Pub 2007. PMID: 17289891.
272. Pai Kasturi S, Qin H, Thomson KS, El-Bereir S, Cha SC, Neelapu S, Kwak LW, Roy K. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. J Control Release 113(3):261-70, 2006. e-Pub 2006. PMID: 16793161.
273. Cha SC, Kwak LW, Ruffini PA, Qin H, Neelapu S, Biragyn A. Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera. J Immunol Methods 312(1-2):79-93, 2006. e-Pub 2006. PMID: 16631194.
274. Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, White T, Harvey L, Pennington R, Stetler-Stevenson M, Jaffe ES, Steinberg SM, Gress R, Hakim F, Wilson WH. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 11(9):986-91, 2005. e-Pub 2005. PMID: 16116429.
275. Neelapu SS, Munshi NC, Jagannath S, Watson TM, Pennington R, Reynolds C, Barlogie B, Kwak LW. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant 36(4):315-23, 2005. e-Pub 2005. PMID: 15968284.
276. Neelapu SS, Baskar S, Gause BL, Kobrin CB, Watson TM, Frye AR, Pennington R, Harvey L, Jaffe ES, Robb RJ, Popescu MC, Kwak LW. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res 10(24):8309-17, 2004. e-Pub 2004. PMID: 15623607.
277. Biragyn A, Ruffini PA, Coscia M, Harvey LK, Neelapu SS, Baskar S, Wang JM, Kwak LW. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood 104(7):1961-9, 2004. e-Pub 2004. PMID: 15191951.
278. Malyguine A, Strobl SL, Shafer-Weaver KA, Ulderich T, Troke A, Baseler M, Kwak LW, Neelapu SS. A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. J Transl Med 2(1):9, 2004. e-Pub 2004. PMID: 15050026.
279. Neelapu S, Figg WD, Dahut W, Reed E. Leptomeningeal carcinomatosis in metastatic prostate cancer. South Med J 95(1):107-8, 2002. e-Pub 2002. PMID: 11827241.
280. Neelapu SS, Baskar S, Kwak LW. Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine. J Cancer Res Clin Oncol 127 Suppl 2:R14-9, 2001. e-Pub 2001. PMID: 11768619.

Invited Articles

1. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22(2):85-96, 2022. e-Pub 2022. PMID: 34002066.
2. Wilson NR, Bover L, Konopleva M, Han L, Neelapu S, Pemmaraju N. CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies. Leuk Lymphoma 63(1):19-30, 2022. e-Pub 2022. PMID: 34486917.
3. Greenbaum U, Kebriaei P, Srour SA, Olson A, Bashir Q, Neelapu SS, Rezvani K, Shpall EJ. Chimeric Antigen Receptor T-cell Therapy Toxicities. Br J Clin Pharmacol 87(6):2414-2424, 2021. e-Pub 2021. PMID: 32463929.
4. Reagan PM, Neelapu SS. How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies. J Clin Oncol 39(5):456-466, 2021. e-Pub 2021. PMID: 33434058.
5. Fang PQ, Gunther JR, Wu SY, Dabaja BS, Nastoupil LJ, Ahmed S, Neelapu SS, Pinnix CC. Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. Front Oncol 11:648655, 2021. e-Pub 2021. PMID: 33842363.
6. Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol 37 Suppl 1:48-52, 2019. e-Pub 2019. PMID: 31187535.
7. Strati P, Neelapu SS. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma. Curr Oncol Rep 21(5):38, 2019. e-Pub 2019. PMID: 30919158.
8. Nair R, Neelapu SS. The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Pract Res Clin Haematol 31(3):293-298, 2018. e-Pub 2018. PMID: 30213399.
9. Sathyanarayanan V, Neelapu SS. Cancer immunotherapy: Strategies for personalization and combinatorial approaches. Mol Oncol 9(10):2043-53, 2015. e-Pub 2015. PMID: 26548534.
10. Cheah CY, Fowler NH, Neelapu SS. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Curr Opin Oncol 27(5):384-91, 2015. e-Pub 2015. PMID: 26248256.
11. Nastoupil LJ, Neelapu SS. Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system. Curr Oncol Rep 17(7):30, 2015. e-Pub 2015. PMID: 25986722.
12. Chu F, Neelapu SS. Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets. Oncoimmunology 3(1):e28101, 2014. e-Pub 2014. PMID: 24808975.
13. Westin JR, Neelapu SS. Therapy of newly diagnosed follicular lymphoma. Front Oncol 2:188, 2012. e-Pub 2012. PMID: 23248775.
14. Kannan S, Neelapu SS. Vaccination strategies in follicular lymphoma. Curr Hematol Malig Rep 4(4):189-95, 2009. e-Pub 2009. PMID: 20425407.
15. Neelapu SS. Choosing treatment options in newly diagnosed patients with multiple myeloma. Community Oncology 6(2):55-58, 2009. e-Pub 2009.
16. Foglietta M, Neelapu SS, Kwak LW. Therapeutic Vaccines for lymphoma: From bench to beside. American Society of Clinical Oncology Education Book, 2009. e-Pub 2009.
17. Park HJ, Neelapu SS. Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br J Haematol 142(2):179-91, 2008. e-Pub 2008. PMID: 18422783.
18. Neelapu SS Kwak LW. Translational development of therapeutic vaccines for lymphomas. American Society of Clinical Oncology Education Book:736-740, 2007. e-Pub 2007.
19. Lee ST, Neelapu SS, Kwak LW. Therapeutic vaccine for lymphoma. Yonsei Med J 48(1):1-10, 2007. e-Pub 2007. PMID: 17326239.
20. Lee ST, Jiang YF, Park KU, Woo AF, Neelapu SS. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. Expert Opin Biol Ther 7(1):113-22, 2007. e-Pub 2007. PMID: 17150023.
21. Neelapu SS, Kwak LW. Vaccine therapy for B-cell lymphomas: next-generation strategies. Hematology Am Soc Hematol Educ Program:243-9, 2007. e-Pub 2007. PMID: 18024636.
22. Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW. Therapeutic lymphoma vaccines: importance of T-cell immunity. Expert Rev Vaccines 5(3):381-94, 2006. e-Pub 2006. PMID: 16827622.
23. Kwak LW, Neelapu SS, Bishop MR. Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. Semin Oncol 31(1):37-46, 2004. e-Pub 2004. PMID: 14970936.
24. Ruffini PA, Neelapu SS, Kwak LW, Biragyn A. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 87(9):989-1001, 2002. e-Pub 2002. PMID: 12217812.

Review Articles

1. Locke FL, Nikiforow S, Frigault MJ, Maloney DG, Davila M, Miklos DB, Lin Y, Vong J, Shah NN, Neelapu SS, Welch J, Ng E, Jacobson C, Maus MV. Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies. Transplant Cell Ther, 2025. e-Pub 2025. PMID: 41207382.
2. Lane DL, Neelapu SS, Xu G, Weaver O. COVID-19 Vaccine-Related Axillary and Cervical Lymphadenopathy in Patients with Current or Prior Breast Cancer and Other Malignancies: Cross-Sectional Imaging Findings on MRI, CT, and PET-CT. Korean J Radiol. e-Pub 2021. PMID: 34719892.
3. Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Hernandez Tejada FN, Martin PL, Auletta J, Choi SW, Bajwa R, Dailey Garnes N, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18(7):435-453, 2021. e-Pub 2021. PMID: 33608690.
4. Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 25(12):2305-2321, 2019. e-Pub 2019. PMID: 31446199.
5. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant 25(4):625-638, 2019. e-Pub 2019. PMID: 30592986.
6. Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, Steiner ME, Cheifetz IM, Lehmann LE, Mejia R, Slopis JM, Bajwa R, Kebriaei P, Martin PL, Moffet J, McArthur J, Petropoulos D, O'Hanlon Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ, (PALISI) Network PALIASI. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol 16(1):45-63, 2019. e-Pub 2019. PMID: 30082906.
7. Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer 6(1):137, 2018. e-Pub 2018. PMID: 30514386.
8. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47-62, 2018. e-Pub 2018. PMID: 28925994.
9. Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica 101(5):531-40, 2016. e-Pub 2016. PMID: 27132279.

Other Articles

1. Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN Erratum to <[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>. Transplant Cell Ther, 2025. PMID: 41067707.
2. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 15(1):5621, 2024. PMID: 38965214.
3. Oluwole OO, Neelapu SS, Ray MD, Limbrick-Oldfield EH, Wade SW, Kanters S, Patel AR, Locke FL Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies. Expert Rev Anticancer Ther 24(6):457-465, 2024. PMID: 38646700.
4. Rezvan A, Romain G, Fathi M, Heeke D, Martinez-Paniagua M, An X, Bandey IN, Montalvo MJ, Adolacion JRT, Saeedi A, Sadeghi F, Fousek K, Puebla-Osorio N, Cooper LJN, Bernatchez C, Singh H, Ahmed N, Mattie M, Bot A, Neelapu S, Varadarajan N Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling. Nat Cancer 5(6):954, 2024. PMID: 38778179.
5. Singh S, Xiao Z, Bavisi K, Roszik J, Melendez BD, Wang Z, Cantwell MJ, Davis RE, Lizee G, Hwu P, Neelapu SS, Overwijk WW, Singh M Correction: IL-1alpha Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol 212(3):500, 2024. PMID: 38088809.

Editorials

1. Ghione P, Palomba ML, Ray MD, Limbrick-Oldfield EH, Owen J, Kanters S, Bobillo S, Ribiero MT, Jacobson CA, Neelapu SS, Ghesquieres H, Nahas M, Beygi S, Patel AR, Gribben JG. A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma. Clin Lymphoma Myeloma Leuk 24(5):e191-e195.e6, 2024. PMID: 38365528.
2. Saini N, Neelapu SS. CAR Treg cells: prime suspects in therapeutic resistance. Nat Med 28(9):1755-1756, 2022. PMID: 36109644.
3. Strati P, Neelapu SS. CAR-T failure: beyond antigen loss and T cells. Blood 137(19):2567-2568, 2021. PMID: 33983421.
4. Green MR, Neelapu SS. Not so FASt: Tumor cells resisting death drive CAR T-cell dysfunction. Cancer Discov 10(4):492-494, 2020. PMID: 32238396.
5. Neelapu SS. A CAR against CAR for unintended consequences. Blood 135(7):460-462, 2020. PMID: 32197269.
6. Coscia M, Bruno B, Neelapu S. Editorial: CAR T-Cell Therapies in Hematologic Tumors. Front Oncol 10:588134, 2020. PMID: 33178614.
7. Neelapu SS. CAR-T efficacy: is conditioning the key?. Blood 133(17):1799-1800, 2019. PMID: 31023743.
8. Neelapu SS, Sharma P. Targeting the tumor niche to treat cancer. Proc Natl Acad Sci U S A 112(42):12907-8, 2015. PMID: 26450879.
9. Neelapu SS. Mutations and microenvironment collude in FL. Blood 125(4):587-9, 2015. PMID: 25614636.
10. Neelapu SS, Kwak LW. Rush hour traffic: directing T cells to tumor. J Natl Cancer Inst 106(11), 2014. PMID: 25255804.
11. Neelapu SS, Kwak LW. Cancer vaccines: up, down, ... up again?. Blood 113(1):1-2, 2009. PMID: 19122114.

Abstracts

1. Manasanch EE, Korde N, Lee HC, Patel K, Becnel M, Berrios D, Thomas SK, Iyer SP, Mailankody S, Amini B, Lin P, Berkova Z, Weber DM, Feng L, Neelapu SS, Jagannath S, Hildebrandt MAT, Orlowski RZ, Landgren O. ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM). ASCO - Journal of Clinical Oncology 41(Suppl 16), 2023. e-Pub 2023.
2. Locke FL, Lekakis LJ, Eradat H, Munoz J, Tees MT, de Vos S, Nath R, Stevens DA, Malik S, Popplewell L, Hamadani M, Oluwole OO, M-A P, Miklos DB, Fisher P, Goyal L, Kaufman G, Kai K, Balakumaran A, Neelapu SS. Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL). ASCO - Journal of Clinical Oncology 41(Suppl 16), 2023. e-Pub 2023.
3. Tang K, Khwaja R, Feng L, Strati P, Steiner RE, Nair R, Flowers CR, Saini N, Ramdial JL, Srour SA, Champlin RE, Rondon G, Torres J, Kebriaei P, Nastoupil LJ, Mistry H, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Ahmed S. Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy. American Society of Hematology Blood 140(Suppl 1):4684-4685, 2022. e-Pub 2022.
4. Ghione P, Palomba ML, Ray MD, Limbrick-Oldfield EH, Owen J, Kanters S, Bobillo S, Ribeiro MT, Jacobson CA, Neelapu SS, Ghesquieres H, Nahas M, Beygi S, Patel AR, Gribben JG. A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL). American Society of Hematology - Blood 140(Suppl 1):4676-4677, 2022. e-Pub 2022.
5. Oluwole OO, Kenderian SS, Shiraz P, Karmali R, Reshef R, McCarthy PL, Ghosh N, Lazaryan A, Filosto S, Poddar S, Mao D, Peng A, Kilcoyne A, Nahas M, Neelapu SS. ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma. American Society of Hematology Blood 140(Suppl 1):10318-10320, 2022. e-Pub 2022.
6. Li X, Deng Q, Henderson J, Watson G, Deaton L, Cain T, Fayad L, Iyer SP, Hagemeister FB, Nastoupil LJ, Fowler NH, Westin J, Steiner R, Nair R, Ahmed S, Alatrash G, Neelapu SS, Strati P, Green MR. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy. American Society of Hematology Blood 140(Suppl 1):4502–4503, 2022. e-Pub 2022.
7. Neelapu SS, Chavez J, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Joseph JD, Yan J, Song Q, Peng W, Lui C, Wulff J, Shen RR, Poddar S, Miao H, Beygi S, Jacobson CA. 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). American Society of Hematology Blood 140(Suppl 1):10380-10383, 2022. e-Pub 2022.
8. H-JJ C, Alig S, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister FB, Rodriguez MA, Lee HJ, McDonnell T, Flowers C, Vega F, Green MR, Alizadeh AA, Richard Davis E, Westin J. Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma. ASCO - Journal of Clinical Oncology 40(Suppl 16), 2022. e-Pub 2022.
9. Khouri IF, Hwang H, Neelapu SS, Wang X, Hosing C, Ahmed S, Kebriaei P, Daher M, Olson AL, Anderlini P, Im JS, Westin J, Shpall EJ, Champlin RE, Nastoupil LJ. Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30. American Society of Hematology Blood 140(Suppl 1):7502-7503, 2022. e-Pub 2022.
10. Jallouk A, Feng L, Noorani M, Das K, Steiner RE, Nastoupil LJ, Hawkins M, Nair R, Westin J, Fayad L, Chihara D, Malpica Castillo LE, Iyer SP, Ahmed S, Shpall EJ, Kebriaei P, Neelapu SS, Strati P. Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy. American Society of Hematology Blood 140(Suppl 1):10424-10426, 2022. e-Pub 2022.
11. Nair R, Prakash R, Dang A, Gunther JR, Huen A, Xu J, Malpica Castillo LE, Cabala CT, Heberton M, Fang P, Ahmed S, Miranda RN, Fayad L, Steiner R, Lee HJ, Chihara D, Jain P, Srour SA, Ramdial JL, Nieto Y, Nastoupil LJ, Pinnix CC, Neelapu SS, Flowers CR, Medeiros LJ, Hosing C, Wang ML, Dabaja BS, Vega F, Feng L, Iyer SP. Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma. American Society of Hematology Blood 140(Suppl 1):12005-12007, 2022. e-Pub 2022.
12. Nair R, Ayers A, Nastoupil LJ, Gunther JR, Fayad L, Fowler NH, Miranda RN, Hagemeister FB, Lee HJ, Rodriguez MA, Steiner R, Strati P, Nieto Y, Ramdial JL, Chihara D, Wang ML, Malpica Castillo LE, Saini N, Jain P, Pinnix CC, Dabaja BS, Green MR, Flowers CR, Medeiros LJ, Marques-Piubelli ML, Vega F, Noorani M, Ahmed S, Westin J, Neelapu SS, Feng L, Iyer SP. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL. American Society of Hematology Blood 140(Suppl 1):3800-3802, 2022. e-Pub 2022.
13. Steiner RE, Strati P, Flowers C, Neelapu SS, Green MR, Nastoupil LJ, Hagemeister FB, Feng L, Ahmed S, Nair R, Fayad L, Lee HJ, Rodriguez MA, Westin J. Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma. ASCO - Journal of Clinical Oncology 40(Suppl 16), 2022. e-Pub 2022.
14. Pinnix CC, Dabaja BS, Gunther JR, Fang P, Wu S, Ahmed S, Steiner RE, Nair R, Strati P, Westin J, Fayad L, Iyer SP, Rodriguez MA, Lee HJ, Samaniego F, Chihara D, Jain P, Feng L, Flowers CR, Neelapu SS, Nastoupil LJ. Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma. American Society of Hematology Blood 140(Suppl 1):3741–3743, 2022. e-Pub 2022.
15. Sheng A, Gordon MJ, Ahmed S, Steiner RE, Strati P, Westin J, Hosing C, Kebriaei P, Shpall EJ, Neelapu SS, Nastoupil LJ. Association of the CLL Comorbidity Index (CLL-CI) and International Prognostic Index (IPI) with Overall Survival (OS) and 1-Year Mortality in Patients (pts) with Relapsed or Refractory (r/r) Large B Cell Lymphoma (LBCL) Treated with CD19 Directed Autologous Chimeric Antigen Receptor T (CART) Cell Therapies. American Society of Hematology Blood 140(Suppl 1):2051-2052, 2022. e-Pub 2022.
16. Jain P, Wang Y, Locke FL, Munoz J, Beitinjaneh A, Frank MJ, Dahiya S, Jacobs MT, Hill BT, Lekakis LJ, Miklos DB, Ghobadi A, Neelapu SS, Lin Y, Wang M, Jain MD, Maurer MJ. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: Real-world experience from the United States lymphoma CAR T consortium. ASCO - Journal of Clinical Oncology 40(Suppl 2), 2022. e-Pub 2022.
17. Agbedia OO, Prakash R, Xu J, Becnel MR, Nair R, Steiner RE, Feng L, Lee HJ, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil LJ, Vo A, Samaniego F, Fowler NH, Saini N, Khouri IF, Im JS, Fayad L, Jain P, Wang ML, Miranda RN, Vega F, Medeiros J, Oki Y, Flowers CR, Neelapu SS, Iyer SP. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis. American Society of Hematology Blood 140(Suppl 1):2313-2315, 2022. e-Pub 2022.
18. Zhang T, Wang Z, S-C C, Anderson A, Liu J, Dong Z, Szymura S, Kuang B, Oh E, Neelapu SS, Kwak LW. Development of a Novel Platform for in-Vitro Immune-Monitoring of Antigen-Specific T Cells and Discovery of Novel Antigen-Specific TCRs Using Immortalized B Cells Transfected with mRNA of Antigen Fused to Mitd (IBMAM). American Society of Hematology Blood 140(Suppl 1):4699-4700, 2022. e-Pub 2022.
19. Neelapu SS, Stevens DA, Hamadani M, Frank MJ, Holmes H, Jacobovits A, Hinkle J, Kennedy-Wilde J, Maller O, Weinstein B, Galimi F, Lai RK, Miklos DB. A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies. American Society of Hematology - Blood 140(Suppl 1):4617-4619, 2022. e-Pub 2022.
20. Locke FL, Neelapu SS, Ray MD, Limbrick-Oldfield EH, Wade SW, Kanters S, Patel AR, Oluwole OO. Network Meta-Analysis (NMA) of Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after 2 Prior Treatments Using Published Comparative Studies. American Society of Hematology Blood 140(Suppl 1):7516-7518, 2022. e-Pub 2022.
21. Mamlouk O, Strati P, Feng L, Sun R, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function. ASCO - Journal of Clinical Oncology 40(Suppl 16), 2022. e-Pub 2022.
22. Strati P, Li X, Deng D, Feng L, Sun R, Jallouk A, Adkins S, Cain T, Johncy S, Steiner RE, Ahmed S, Chihara D, Fayad L, Iyer SP, Horowitz SB, Nehlsen R, Nastoupil LJ, Ranjit Nair R, Hassan A, Daoud T, Hawkins M, Samaniego F, Rodriguez MA, Shpall EJ, Kebriaei P, Flowers CR, Hong D, Westin J, Neelapu SS, Green MR. Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma. American Society of Hematology Blood 140(Suppl 1):7493-7495, 2022. e-Pub 2022.
23. Oluwole OO, Kenderian SS, Shiraz P, Karmali R, Reshef R, McCarthy PL, Ghosh N, Lazaryan A, Filosto S, Poddar S, Mao S, Peng P, Kilcoyne A, Nahas M, Neelapu SS. ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma. American Society of Hematology Blood 140(Suppl 1):10318–10320, 2022. e-Pub 2022.
24. Jain H, Karulkar A, Sharma N, Sengar M, Jaiswal A, Shah S, Khan A, Firfiray A, Asija S, Suvasia P, Suvasia P, Pendhari J, Kalra D, Ravikumar S, Narula G, Banavali S, Poojary M, Hiregoudar S, Nayak L, Bagal B, Tembhare PR, Epari S, Khattry N, Patkar N, Gujral S, Shet T, Subramanian PG, Thorat J, Punatar S, Gokarn A, Ghosh K, Agarwal A, Desai P, Ojha S, Yadav S, Bhosale SP, Rajadhyaksha S, Navkudkar A, Laskar S, Mirgh SP, Nisar A, Pandit D, Patil R, Purwar R, Neelapu SS, Shah NN. Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy. American Society of Hematology Blood 140(Suppl 1), 2022. e-Pub 2022.
25. Lunning MA, H-L W, Z-H H, Locke FL, Siddiqi T, Jacobson CA, Ahmed S, Miklos DB, Lin Y, Hill BT, Ghobadi A, Neelapu SS, Westin J, Miao H, Shahani S, Patel AR, Spooner C, Fu C, Xu H, Pasquini MC. Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy. American Society of Hematology Blood 140(Suppl 1):1852-1855, 2022. e-Pub 2022.
26. Jain N, Ferrajoli A, Yilmaz M, Thompson PA, Konopleva, M Green MR, Sampath D, Neelapu SS, Takahashi K, Masarova L, Burger JA, Kanagal-Shamanna R, Khoury JD, Garg N, Su X, Wang X, Patel H, Ayala A, Kantarjian H, Keating MJ, Wierda WG. Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
27. Nair R, Feng L, Gunther JR, Xu J, Malpica-Castillo L, Huen A, Torres Cabala C, Heberton M, Fang P, Ahmed S, Miranda RN, Fayad L, Steiner R, Lee HJ, Chihara D, Jain P, Srour SA, Nieto Y, Nastoupil L, Pinnix CC, Neelapu SS, Flowers CR, Medeiros LJ, Hosing C, Wang M, Dabaja BS, Vega F, Iyer SP. Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
28. Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedellv PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL). American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
29. Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson ML, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt JD, Sherman M, Dong J, Giovanetti A, Yang Y, Lui C, Bashir Z, Jung AS, Jacobson C. Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
30. Pinnix CC, Dabaja BS, Gunther JR, Fang P, Wu S, Nastoupil L, Strati P, Nair R, Ahmed S, Steiner RE, Malpica-Castillo L, Chihara D, Jain P, Fayad L, Westin JR, Neelapu SS, Rodriguez MA, Hagemeister FB, Lee HJ, Wang M, Samaniego F, Fowler NH, Flowers CR, Feng L, Chi L, Esmaeli B. Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
31. Jain N, Ferrajoli A, Thompson PA, Konopleva M, Green MR, Sampath D, Neelapu SS, Takahashi K, Strati P, Burger JA, Kanagal-Shamanna R, Khoury JD, Garg N, Su X, Wang X, Patel H, Ayala A, Kantarjian H, Keating MJ, Wierda WG. Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
32. Al Zaki A, Westin JR, Watson G, Feng L, Ahmed S, Mistry H, Nastoupil L, Hawkins M, Nair R, Iyer SP, Lee H, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Strati P. Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
33. Spiegel JY, Jain MD, Nastoupil L, Tamaresis J, Ghobadi A, Lin Y, Lekakis LJ, Reagan PM, Oluwole OO, McGuirk JP, Deol A, Sehgal AR, Goy AH, Hill BT, Andreadis C, Muñoz J, Ulrickson ML, Westin JR, Chavez JC, Jacobs MT, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Dahiya S, Lunning MA. Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
34. Song Q, Hu T, Neelapu SS, Locke FL, Jacobson C, Miklos DB, Oluwole OO, Kersten MJ, Topp M, Kim JJ, Singh K, Andrade J, Huang L, Xue A, Schupp M, Nahas M, Shen RR, Bot A. Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events after Axicabtagene Ciloleucel in Large B-Cell Lymphoma Based on Machine Learning Algorithms. American Society of Hematology (Blood) 138(Suppl 15), 2021. e-Pub 2021.
35. Neelapu SS, Hamadani M, Stevens D, Hayes SM, Galimi F, Miklos DB. A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
36. Westin JR, Steiner R, Feng L, Strati P, Flowers CR, Neelapu SS, Nastoupil L, Chihara D, Hagemeister FB, Ahmed S, Nair R, Fayad L, Lee HJ, Rodriguez MA, Davis E, Green MR. Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
37. Jacobson C, Locke FL, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy AH, Muñoz J, Siddiqi T, Shen RR, Bot A, Dong J, Singh K, Spooner C, Karalliyadda R, Kim JJ, Zheng Y, Neelapu SS. Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL). American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
38. Malpica-Castillo L, Feng L, Xu J, Nair R, Elias A, Jain P, Chihara D, Steiner R, Fayad L, Samaniego F, Ahmed S, Fowler NH, Nastoupil L, Srour SA, Nieto Y, Hosing C, Miranda RN, Vega F, Pinnix CC, Gunther JR, Fang P, Wu S, Dabaja BS, Medeiros J, Wang M, Neelapu. Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
39. Steiner RE, Strati P, Flowers CR, Neelapu SS, Green MR, Nastoupil L, Hagemeister FB, Feng L, Ahmed S, Nair R, Fayad L, Lee HJ, Rodriguez MA, Westin JR. Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
40. Chihara D, Nastoupil L, Strati P, Samaniego F, Feng L, Rodriguez MA, Fayad L, Westin JR, Hagemeister FB, Wang M, Neelapu SS, Fowler NH. Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
41. Nair R, Feng L, Gunther JR, Xu J, Malpica-Castillo L, Huen A, Torres Cabala C, Heberton M, Fang P, Ahmed S, Miranda RN, Fayad L, Steiner R, Lee HJ, Chihara D, Jain P, Srour SA, Nieto Y, Nastoupil L, Pinnix CC, Neelapu SS, Flowers CR, Medeiros LJ, Hosing C, Wang M, Dabaja BS, Vega F, Iyer SP. Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
42. H-JJ1 C, Sun R, Yang H, Deng Q, Fayad L, Fowler NH, Parmar S, Ahmed S, Steiner RE, Hagemeister FB, Lee HJ, Nair R, Rodriguez MA, Samaniego F, Iyer SP, Nastoupil L, Neelapu SS, Strati P, Westin JR, Green MR. A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
43. Palomba LL, Ghione P, Patel AR, Deighton K, Jacobson C, Nahas M, Scott Jung A, Hatswell AJ, Kanters S, Limbrick-Oldfield E, Wade SW, Snider JT, Neelapu SS, Riberio MT, Gribben J, Radford J, Bobillo S, Ghesquieres H. A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL). American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
44. Neelapu SS, Nath R, Munoz J, Tees M, Miklos DB, Frank MJ, Malik SA, Stevens D, Shin CR, Balakumaran A, Loomis-Navale L, Goyal L, Nguyen A, Locke FL. ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
45. Wang Y, Jain P, Locke FL, Munoz J, Maurer MJ, Beitinjaneh A, Frank MJ, Dahiya S, McGuirk JP, Jacobs MT, Goy AH, Vose JM, Hill BT, Oluwole OO, Deol A, Shah BD, Paludo J, Wang T, Lekakis LJ, Miklos DB, Rapoport AP, Ghobadi A, Neelapu SS, Lin Y, Wang M, Jain MD. Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
46. Lekakis LJ, Locke FL, Tees M, Neelapu SS, Malik SA, Hamadani M, Frank MJ, Popplewell LL, Abramson JS, de Vos S, Munoz J, Shin CR, Balakumaran A, Loomis-Navale L, Goyal L, Zhou X, Miklos DB. ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
47. Munshi PN, Casulo C, Maloney D, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwold OO, Fung HCH, Rosenblatt JD, Rossi JM, Goyal L, Plaks V, Yang Y, Lee J, Godfrey W, Vezan R, Avanzi MP, Neelapu SS. Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
48. Thomas SK, S-C C, Parshottam SP, Rao SS, Olsem JB, Crumpton BN, Szymura S, Wang Z, Anderson A, Feng L, Lee HC Manasanch EE, Patel KK, Weber DM, Orlowski RZ, Neelapu SS, Kwak LW. A Novel Therapeutic DNA Vaccine Elicits Reduction of Tumor Clones and Favorable Perturbations in the Immune Microenvironment in Patients (pts) with Untreated Smoldering Waldenström Macroglobulinemia (sWM). American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
49. Srour SA, Xu J, Al-Juhaishi T, Steiner RE, Ensor J, Ahmed S, Parmar S, Strati P, Nastoupil LJ, Nieto Y, Hosing C, Lee JH, Westin J, Fowler NH, Fayad L, Dabaja BS, Pinnix CC, Gunther JR, Fang P, Samaniego F, Jain P, Champlin RE, Khouri IF, Wang M, Miranda RN, Vega F, Neelapu S, Flowers C, Iyer SP. Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
50. Gouni S, Strati P, Westin J, Nastoupil LJ, Steiner RE, Nair R, Fayad L, Neelapu SS, Landgraf R, Bilbao D, Vega F, Agarwal N. Use of Medium Potency Statins Is Associated with Improved Outcomes after Frontline RCHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL). American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
51. Jain P, Yao Y, Zhao S, Liu Y, Hill H, Che Y, Li Y, Jordan AA, McIntosh J, Lee HJ, Steiner RE, Samaniego F, Westin J, Nastoupil LJ, Nair R, Ahmed S, Ok CY, Kanagal-Shamanna R, Oriabure O, Xu G, Chen W, Moghrabi O, McClain CM, Badillo M, Thirumurthi S, Santo D, Iliescu C, Yin CC, Shaoying L, Guilin T, Vega F, Neelapu SS, Flowers C, Wang L, Wang M. Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) – a Phase II Clinical Trial. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
52. Chavez JC, Jacobson CA, Sehgal AR, Neelapu SS, Maloney DG Salles G, William BM, Yang Y, Goyal L, Chou J, Plaks V, Avanzi MP. Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
53. Iyer SP, Xu J, Becnel MR, Nair R, Steiner R, Feng L, Lee HJ, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil LJ, Vo A, Samaniego F, Fowler NH, Saini N, Khouri IF, IM JS, Jain P, Fayad L, Wang M, Miranda RN, Vega F, Flowers C, Neelapu SS. A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
54. H-JJ C, Steiner RE, FAyad L, Strati P, Nair R, Hagemeister FB, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers C, Samaniego F, Rodriguez MA, Feng L, Chuang H, Westin JR. Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
55. Strati P, Samaniego F, Gallardo M, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Kangal-Shamanna R, Vega F, Fowler NH, Flowers CR, Nastoupil LJ. Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
56. Saini N, C-C C, Strati P, Natoupil LJ, Westin J, Nair R, FAyad L, Ahmed S, Lee HJ, Iyer SP, Steiner RE Greenbaum U, Kebriaei P, Shpall EJ, Jain N, Green MR, Ajami NJ, Flowers C, Champlin RE, Wargo J, Neelapu SS, Jeng RR. Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
57. Jacobson CA, Locke FL, Miklos DB, Vose JM, Lin Y, Budde LE, Maloney DG, Jaglowski S, Riedell PA, Lekakis LJ, M-A P, Kim JJ, Kawashima J, Yang Y, Rossi JM, Goyal L, Neelapu SS. Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
58. Kenderian SS, Oluwole OO, McCarthy PL, Reshef R, Shiraz P, Ahmed O, Gall JL, Nahas M, Tang L, Neelapu SS. ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi‑Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL). American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
59. Strati P, Mistry H, Pulsifier B, FAyad L, Ahmed S, Lee JH, Iyer SP, Nair R, Nastoupil LJ, Parm S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Dabaja Bouthaina BS, Noorani M, Claussen CM, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Neelapu SS. Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
60. Neelapu SS, Ulrickson ML, Oluwole OO, Herrera AF, Thieblemont C, Ujjani CS, Lin Y, Riedell PA, Kekre N, deVos S, Yang Y, Milletti F, Goyal L, Kawashima J, Chavez JC. Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL). American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
61. Manasanch EE, Han G, Zhang Z, Dang M, Singh M, Khan M, Singh S, Lee HC, Patel KK, Kaufman GP, Amini B, Bashir Q, Srour SA, Nieto Y, Qazilbash MH, Berkova Z, Lin P, Berry D, Thomas SK, Weber DM, Futreal A, Wang L, Orlowski R, Neelapu SS. Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma. American Society of Hematology (Blood), 2020. e-Pub 2020.
62. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad L, Lee HJ, Iyer SP, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers C, Tummala S, Ramdial J, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
63. Neelapu SS, Munoz J, Lundry Locke F, Miklos DB, Brown R, McDevitt JT, Mardiros A, Demirhan E, Konto C, MT; T. First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study. Journal of Clinical Oncology (ASCO) 38(Suppl 1), 2020. e-Pub 2020.
64. Nair R, Pinnix CC, Gunther JR, Strati P, Westin J, Fayad L, Hagemeister FB, Iyer SP, Nastoupil LJ, Parmar S, Rodriguez MA, Steiner R, Dabaja BS, Fang P, Flowers C, Noorani M, Feng L, Neelapu SS, Ahmed S, Lee HJ. M.D. Anderson experience of immune checkpoint inhibitor therapy in classical Hodgkin lymphoma. Journal of Cliniical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
65. Galon J, Scholler N, Perbost R, Turcan S, Danan C, Lundry Locke F, Neelapu SS, Miklos DB, Jacobson CA, Lekakis LJ, Lin Y, Ghobadi A, Chou J, Wang Z, Xue A, Rossi JM, Bot A. Tumor microenvironment associated with increased pretreatment density of activated PD-1+ LAG-3+/− TIM-3− CD8+ T cells facilitates clinical response to axicabtagene ciloleucel (axi-cel) in patients (pts) with large B-cell lymphoma. Journal of Clinical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
66. Chin CK, Lim KJC, Lewis KL, Jain P, Yg Q, Feng L, Cheah C, Seymour JF, Ritchie D, Burbury K, Si Lun Tam C, Fowler NH, Fayad L, Westin J, Neelapu SS, Hagemeister FB, Samaniego F, Flowers C, Nastoupil LJ, Dickinson M. Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: An international, multicenter propensity matched study. Journal of Clinical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
67. Strati P, Furqan F, Westin J, Fayad L, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Simrit Parmar S, Rodriguez MA, Samaniego F, Steiner R, Wang M, Pinnix CC, Flowers C, Horowitz SB, Classen C, Mistry H, Neelapu SS. Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel). Journal of Clinical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
68. Ahmed S, Furqan F, Strati P, Westin J, Fayad L, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner R, Wang M, Pinnix CC, Flowers C, Horowitz SB, Hawkins M, Neelapu SS. . Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel). Journal of Clinical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
69. Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles GA, Casulo C, Munshi PN, Maloney DG, De Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HC, Plaks V, Yang Y, Lee J, Avanzi MP, Neelapu SS. Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL). Journal of Clinical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
70. Lundry Locke F, Bartlett NL, Jacobson CA, Oluwole OO, Munoz J, Lekakis LT, Topp MS, Avivi I, Kim JJ, Chu R, Zheng L, Rossi JM; Bot A, Neelapu SS. Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1. Journal of Clinical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
71. Chin CK, Cheah C, Jain P, Fowler NH, Fayad L, Westin J, Rodriguez MA, Noorani M, Neelapu SS, Hagemeister FB, Medeiros LJ, Vega F, Samaniego F, Flowers C, Nastoupil L. Clinicopathologic features and outcomes of de novo transformed indolent lymphoma. Journal of Clinical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
72. Abbas H, Alfayez M, Garcia-Manero G, Ravandi F, Kadia TM, Dinardo CD, Mathews J, Flores W, Andreeff M, Kornblau SM, Konopleva M, Cortes JE, Neelapu SS, Kantarjian HM, Davis RE, Guastad Daver N. IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): A subset analysis of a phase 2 study. Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
73. Neelapu SS, Chavez JC, Lin Y, Munoz L, Ujjani CS, Riedell P, De Vos S, Oluwole OO, Kekre N, Yang Y, Goyal L, Backhouse K, Milletti F, Kawashima J, Francisco Herrera A. ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL). Journal of Clinical Oncology 37(Suppl), 2019. e-Pub 2019.
74. Anand K, Burns E, Sano D, Pingali SR, Westin J, Nastoupi LJ, Lee HJ, Samaniego F, Parmar S, Wang M, Hawkins M, Adkins S, Fayad L, Steiner S, Nair R, Ahmed S, Fowler NH, Neelapu SS, Iyer SP. Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS. Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
75. Thomas SK, Cha S, Parshottam SP, Rao SS, Olsem JB, Crumpton BN, Feng L, Lee HC, Manasanch EE, Weber DM, Patel KK, Orlowski RZ, Neelapu SS, Kwak LW. Phase I trial of a novel DNA vaccine in patients (pts) with smoldering Waldenstrom macroglobulinemia (sWM). Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
76. Strati P, Adkins S, Nastoupil LJ, Westin J, Hagemeister FBH, Fowler NH, Lee HJ, Fayad L, Samaniego F, Ahmed S, Varma A, Arafat S, Johncy S, Kebriaei P, Mulanovich V, Ariza-Heredia E, Neelap SS. Hematopoietic recovery and immune reconstitution after axi-cel CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma. Jpurnal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
77. Strati P, Ahmed MA, Fowler NH, Hagemeister FB, Fayad L, Rodriguez MA, Samaniego F, Wang M, Westin J, Romaguera JE, Noorani M, Phansalkar K, Cheah C, Feng L, Davis RE, Nastoupil LJ, Neelapu SS. Prognostic value of baseline SUVmax in patients with advanced stage follicular lymphoma receiving frontline rituximab-based therapy. Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
78. Spiegel JY, Dahiya S, Jain MD, Nastoupil LJ, Ghobadi A, Lin Y, Lunning MA, Reagan PM, McGuirk J, Deol A, Munoz J, Locke FL, Neelapu SS, Tamaresis JS, Rapoport A, Miklos DB, Hill BT. Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US lymphoma CAR-T consortium. Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
79. Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Srour S, Bashir Q, Qazilbash MH, Weber DM, Neelapu SS, Orlowski RZ, Feng L, Lin P, Manasanch EE. Correlation of minimal residual disease negativity (MRD-) with prognosis in high-risk myeloma (HRM). Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
80. Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, Bartlett NL, Braunschweig I, Jiang Y, Kim JJ, Zheng L, Rossi JM, Lundry Locke F. Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B cell lymphoma (LBCL). Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
81. Westin JR, Nastoupil LJ, Fayad L, Hagemeister FB, Oki Y, Turturro F, Ahmed S, Rodriguez MA, Lee HJ, Steiner RE, Nair R, Parmar S, Young KH, McDonnell TJ, Chuang H, Green MR, Neelapu SS, Davis E. Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma. Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
82. Lundry Locke F, Ghobadi A, Lekakis LL, Miklos DB, Jacobson CA, Jacobsen ED, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Reagan PM, Farooq U, Deol A, Bot A, Rossi JM, Jiang Y, Xue A, Go WY, Neelapu SS. Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. Journal of Clinical Oncology 36(Suppl), 2018. e-Pub 2018.
83. Locke FL, Ghobadi A, Jacobson CA, Jacobsen ED, Miklos DB, Lekakis LJ, Braunschweig I, Oluwole OO, Lin Y, Siddiqi T, Deol A, Reagan PM, Farooq U, Bot A, Jiang Y, Rossi JM, Xue A, Go WY, Neelapu SS. Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. Journal of Clinical Oncology (ASCO) 36(Suppl), 2018. e-Pub 2018.
84. Westin JR, Oki Y, Nastoupil L, Fayad L, Neelapu SS, Turturro F, Hagemeister FB, Rodriguez MA, Lee HJ, Young KH, McDonnell TJ, Ford RJ, Davis RE. Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results. Blood (59th Annual Meeting), 2017. e-Pub 2017.
85. Claussen, CM, Chuang T, Chaudhry M, Lee HC, Patel KK, Bashir Q, Parmar S, Ahmed S, Mehta RS, Thomas SK, Rachards TA, Nieto Y, Shpall EJ, Qazilbash MH, Amini B, Davis RE, Neelaps SS, Weber DM, Orlowski RZ, Feng L, Manasanch EE. Gene Expression Profiling Is a Strong Predictor of Clinical Outcomes in Newly Diagnosed Multiple Myeloma. Blood (59th Annual Meeting), 2017. e-Pub 2017.
86. Mathur R, Barnett BE, Hermanson D, He J, Zhang Z, Rengarajan S, Codde R, Wang X, Tan Y, Martin C, Smith J, Lee HC, Manasanch EE, Thomas SK, Patel K, Weber DM, Davis RE, Orlowski RZ, Ostertag EM, Shedlock D, Yang J, Neelapu SS. B-Cell Maturation Antigen (BCMA)-Specific, CentyrinTM-Based, PiggyBacTM-Transposed CAR-T Memory Stem Cells Are Effective Against p53-/- and Patient-Derived Multiple Myeloma Tumors. Blood (59th Annual Meeting), 2017. e-Pub 2017.
87. Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Reagan PM, Bot A, Rossi JM, Sherman M, Navale L, Jiang Y, Aycock JS, Elias M, Wiezorek JS, Go WY, Miklos DB. Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL). Blood (59th Annual Meeting), 2017. e-Pub 2017.
88. Becnel MR, Nastoupil L, Davis RE, Hagemeister FB, Fanale MA, Fayad L, Westin JR, Wang M, Oki Y, Claret L, Forbes SG, Feng L, Samaniego F, Neelapu SS, Fowler N. Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial. Blood (59th Annual Meeting), 2017. e-Pub 2017.
89. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobsen ED, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Reagan PM, Bot A, Rossi JM, Navale L, Jiang Y, Aycock JS, Elias M, Wiezorek JS, MD, Go WY. Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). BLOOD (59th Annual Meeting), 2017. e-Pub 2017.
90. Li L, Muftuoglu M, Liu E, Ang S, LV J, Wan X, Cai R, Chen H, Hu B, Jimenez J, Mak D, Burks JK, Bdiwi MH, Banerjee PP, Imahashi N, Kerbbauy LN, Lu J, FLWI L, Mndt MC, Depombo A, Daher M, Basar R, Neelapu SS, Orlowski RZ, Andreeff M, Marin DC, Champlin RE Shpall EJ, Rezvani K. CS1-Specific Chimeric Antigen Receptor Drives Cord Blood NK Cell Maturation and Expansion In Vivo . Blood (59th Annual Meeting), 2017. e-Pub 2017.
91. Chihara D, Dabaja BS, Oki Y, Westin JR, Cheah CY, Pinnix CC, Neelapu SS, Fanale MA, Fowler NH, Nastoupil L. The Role of Radiation Therapy and Risk of Developing Secondary Gastric Cancer in Patients Presenting with Early Stage Gastric Lymphoma. Blood (59th Annual Meeting), 2017. e-Pub 2017.
92. Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil L, Westin JR, Fayad LE, Neelapu SS, Cheah CY. Difference in Survival Outcome of Primary Central Nervous System Lymphoma By Histologic Types. Bolld (59th Annual Meeting), 2017. e-Pub 2017.
93. Mathur R, Zhang Z, He J, Galetto R, Gouble A, Chion-Sotinel I, Filipe S, Gariboldi A, Veeramachaneni T, Manasanch EE, Thomas SK, Lee HC, Patel K, Weber DM, Davis RE, Orlowski RJ, Smith J, Yang J, Neelapu SS. Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma . Blood (59th Annual Meeting), 2017. e-Pub 2017.
94. Hermanson D, Barnett BE, Rengarjan S, Codde R, Martin CE, Wang X, Tan Y, Smith JB, He J, Mathur R, Neelapu SS, Yang J, Ostertag EM, Devon SJ. PiggyBac-manufactured anti-BCMA Centyrin-based CAR-T therapeutic. Proceedings of the American Association for Cancer Research 58, 2017. e-Pub 2017.
95. Qin H, Wei G, Sakamaki I, Dong Z, Cheng WA, SmithDL, Wen F, Sun H, Cha S, Neelapu SS, Kwak LW. Drug resistant B-cell tumors eliminated by novel therapeutic antibodies. Proceedings of the 110th Annual Meeting of the American Association for Cancer Research 58, 2017. e-Pub 2017.
96. Roschewski M, Dunleavy K, Neelapu SS, Pittaluga S, Melani CJ, Jaffe ES, Shovlin M, Crossley B, Kong K, Jacob A, Kwak L, Wilson WH. Quantitative Baseline Circulating Tumor DNA Levels Correlate with GM-CSF Response to Idiotype Vaccine in Untreated Mantle Cell Lymphoma. Blood (58th Annual Meeting) 128(22):2943, 2016. e-Pub 2016.
97. Simar KA, Sathyanarayanan V, Issa AK, Ahmed MA, Noorani M, Fanale MA, Oki Y, Hagemeister FB, Neelapu SS, Nastoupil L, Fowler N, Turturro F, Davis R, Rodriguez MA, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience. Blood (58th Annual Meeting) 128(22):4208, 2016. e-Pub 2016.
98. Hermanson DL, Barnett BE, Rengarajan S, Codde R, Wang X, Tan Y, Martin CE, Smith JB, He J, Mathur R, Yan J, Neelapu SS, Osertag EM, Shedlock DJ. A Novel Bcma-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma. Bloof (58th Annual Meeting) 128(22):2943, 2016. e-Pub 2016.
99. Claussen CM, Lee H, Shah JJ, Richards T, Shah N, Patel K, Bashir Q, Parmar S, Thomas S, Nieto Y, Qazilbash MH, Davis RE, Neelapu SS, Weber DM, Orlowski RZ, Feng L, Manasanch EE. Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. Blood (58t Annual Meeting) 128(22), 2016. e-Pub 2016.
100. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang W, Fowler N, Medeiros LJ, Davis RE, Oki Y. The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma. Blood (58th Annual Meeting) 128(22):4153, 2016. e-Pub 2016.
101. Westin JR, Sathyanarayanan V, Fayad LE, Nastoupil LJ, Turturro F, Hagemeister FB, Simar KA, Young KH, McDonnell TJ, Chuang H, Kamil F, Feng L, Davis ER, Neelapu SS, Oki Y. Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Phase I Results. Blood (58t Annual Meeting) 128(22):5395, 2016. e-Pub 2016.
102. S1 N, Locke FL, Bartlett NL, Lekakis L, Miklos D, Jacobson CA, Braunschweig I, Oluwole O, Siddiqi T, Lin Y, Timmerman J, Stiff PJ, Friedberg J, Flinn I, Goy A, Smith M, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Reagan P, Bot A, Rossi JM, Navale L, Jiang Y, Aycock JS, Elias M, Wiezorek J, Go WY. LBA-6 Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 ZUMA-1. Blood (58th Annual Meeting) 128(22):998, 2016. e-Pub 2016.
103. Jain N, Basu S, Thompson PA, Ohanian M, Ferrajoli A, Pemmaraju N, Cortes JE, Estrov Z, Burger JA, Neelapu SS, Lopez W, Thakral B, Bueso-Ramos CE, Blando J, O'Brien SM, Kantarjian HM, Allison J, Keating M, Sharma P, Wierda WG. Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial. Blood (58th Annual Meeting) 128(22):59, 2016. e-Pub 2016.
104. Takahashi K, Wang F, Kantarjian HM, Denaha D, Khann K, Patel KP, Neelapu SS, Gumbs C, Bueso-Ramos CE, DiNardo CD, Colla S, Ravandi F, Zhang J, Wu X, Samaniego F, Garcia-Manero G, Futreal A. Clonal Hematopoiesis Increases Risk of Therapy-Related Myeloid Neoplasms. Blood (58th Annual Meeting) 128(22):38, 2016. e-Pub 2016.
105. Gomes da Silva D, Mukherjee M, Srinivasan M, Dakhova O, Liu H, Grilley B, Gee AP, Neelapu SS, Rooney CM, Heslop HE, Savoldo B, Dotti G, Brenner MK, Mamonkin M, Ramos CA. Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling. Blood (58th Annual Meeting) 128(22):1851, 2016. e-Pub 2016.
106. Sathyanarayanan V, Oki Y, Issa AK, Ahmed MA, Noorani M, Fanale MA, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler N, Turturro F, Davis ER, Rodriguez A, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy-the University of Texas MD Anderson Experience. Blood (58th Annual Meeting) 128(22):106, 2016. e-Pub 2016.
107. Hu B, Younes A, Claret L, Feng L, Westin JR, Fowler N, Neelapu SS, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Nastoupil LJ, Copeland AR, Fanale MA, Oki Y. The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL). Blood (58th Annual Meeting) 128(22):1833, 2016. e-Pub 2016.
108. Neelapu SS, Locke FL, Bartlett NL, Siddiqi T, Chavez JC, Hosing C, Cashen AF, L Elizabeth Budde L, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Wiezorek JS, Go WY. Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL). J Clin Oncol (ASCO Annual Meeting 2016) 34((suppl; abstr 7559)), 2016. e-Pub 2016.
109. Crump M, Neelapu SS, Farooq U, Den Neste EV, Kuruvilla J, Ahmed MA, Link BK, Hay AE, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek JS, Go WY, Gisselbrecht C. Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study. J Clin Oncol (ASCO Annual Meeting 2016) 34((suppl; abstr 7516)), 2016. e-Pub 2016.
110. Westin JR, Oki Y, Fayad L, Nastoupil LJ, Turturro F, Hagemeister FB, Sathyanarayanan V, Young KH, McDonnell T, Chuang H, Zhou S, Neelapu SS, Davis RE. Rituximab, lenalidomide, and ibrutinib alone and combined with dose adjusted chemotherapy for patients with high risk diffuse large B-cell lymphoma. J Clin Oncol (ASCO Annual Meeting 2016) 34((suppl; abstr TPS7575)), 2016. e-Pub 2016.
111. Issa A, Sathyanarayanan V, Fanale MA, Oki Y, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler NH, Turturro F, Noorani M, Ahmed MA, Davis RE, Rodriguez MA, Wang M, Feng L, Young KH, McDonnell T, Pinnix CC, Fayad L, Westin JR. Outcomes of diffuse large b-cell lymphoma with MYC and/or BCL2 protein expression treated with intensive chemotherapy. J Clin Oncol (ASCO Annual Meeting 2016) 34((suppl; abstr 7563)), 2016. e-Pub 2016.
112. Overman MJ, Lopez CD, Benson AB, Neelapu SS, Mettu NB, Ko AH, Chung VM, Nemunaitis JJ, Reeves JA, Bendell JC, Philip PA, Dalal R, Fardis M, Greer J, Wang X, Inamdar S, Lannutti BJ, Rothbaum W, Izumi R, Javle MM. A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC). J Clin Oncol (ASCO Annual Meeting 2016) 34((suppl; abstr 4130)), 2016. e-Pub 2016.
113. Ghobadi A, Locke FL, Neelapu SS, Siddiqi T, Chavez JC, Hosing CM, Bartlett NL, Budde LE, Bot A, Rossi JM, Sherman M, Navale L, Elias M, Wiezorek J, Go WY. Updated phase I results from ZUMA-1: a phase I-II multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive non-Hodgkin lymphoma (NHL). Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, 2016. e-Pub 2016.
114. Takahashi K, Wang F, Kantarjian H, Denaha D, Thompson E, Gumbs C, Patel K, Neelapu S, Wang Y, Bohannan Z, DiNardo C, Ravandi F, Estrov Z, Colla S, Zhang J, Wu X, Garcia-Manero G, Futreal A. Clonal origin of therapy-related myeloid neoplasms. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, 2016. e-Pub 2016.
115. Sehgal L, Jain N, Khashab T, wang X, Neelapu S, Samaniego F. Targeting mir101/ EZH2/NFkb axis by FGFR1 inhibitor in mantle cell lymphoma. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, 2016. e-Pub 2016.
116. Chihara D, Ahmed MA, Oki Y, Westin JR, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez A, Fowler N, Wang M, Fayad LE, Davis RE, Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood (57th ASH Annual Meeting) 126(23):1502, 2015. e-Pub 2015.
117. Fowler N, Pinto RM, Cheah CY, Neelapu SS, Turturro F, Hagemeister FB, Romaguera JE, Fanale MA, Fayad LE, Forbes S, Khan J, Feng L, Samaniego F, Nastoupil L. A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma. Blood (57th Annual ASH Meeting) 126(23):2742 - 2742, 2015. e-Pub 2015.
118. Sehgal L, Tamer K, Wang X, Mathur R, Berkova Z, Romaguera JE, Rodriguez A, Neelapu SS, Samaniego F. Tumor Microenvironment Regulates Survival of Mantle Cell Lymphoma Cells through Various Signaling Pathways. Blood (57th ASH Annual Meeting) 126(23):4775, 2015. e-Pub 2015.
119. Wang Y, Wagner-Bartak N, Zhou S, Fowler N, Dela Rosa ML, Zhao D, Romaguera JE, Neelapu SS, Hagemeister FB, Fanale MA, Oki Y, Shah JJ, Thomoas SK, Hosing CM, Zhang L, Badillo M, Chen W, Cai Q, Zou D, Champlin RE, Fayad LE, Lee HJ, Wang M. Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial. Blood (57th Annual ASH Meeting) 126(23):3969 - 3969, 2015. e-Pub 2015.
120. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. Blood (57th Annual ASH Meeting) 126(23), 2015. e-Pub 2015.
121. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen J, Wang Z, Ma W, Lee H, Orlowski RZ, Sarbassov DD, Neelapu SS, McDonnell TJ, Miranda RN, Wang M, Kantarjian HM, Konopleva M, Davis RE, Andreeff M. ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response. Blood (57th ASH Annual Meeting) 123(23):2051, 2015. e-Pub 2015.
122. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. Blood (57th Annual ASH Meeting) 126(23), 2015. e-Pub 2015.
123. Younes A, Berdeja JG, Patel MR, Kelly KR, Flinn IW, Gerecitano JF, Neelapu SS, Copeland AR, Akins A, Clancy M, Ma A, Sun K, Tian Z, Wang J, Viner J, Oki Y. Phase 1 Trial Testing Single Agent CUDC-907, a Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma. Blood (ASH 57th Annual Meeting) 126(23):257, 2015. e-Pub 2015.
124. Claussen CM, Chuang T, Shah J, Lee H, Shah N, Patel KK, Bashir Q, Parmar S, Thomas S, Qazilbash M, Davis RE, Neelapu SS, Weber D, Orlowski RZ, Feng L, Manasanch EE. Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. Blood (ASH 57th Annual Meeting) 126(23):5390, 2015. e-Pub 2015.
125. Rossi JM, Neelapu SS, Go WY, Shen Y, Sherman M, Locke FL, Bartlett NL, Siddiqi T, Navale L, Elias M, Wiezorek J, Bot A. Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). Blood (57th ASH Annual Meeting) 126(23):2730, 2015. e-Pub 2015.
126. Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Navale L, Aycock JS, Wiezorek J, Go WY. Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). Blood (57th ASH Annual Meeting) 126(23):3991, 2015. e-Pub 2015.
127. Younes A, Patel MR, Oki Y, Flinn IW, Gerecitano JF, Neelapu SS, Copeland A, Akins AJ, Clancy MS, Viner J, Wang J, Atoyan R, Berdeja JG. A First-in-Human Trial of CUDC-907, an Oral, First-in-Class, Dual Inhibitor of PI3K and HDAC, in Patients with Refractory/Relapsed Lymphoma and Multiple Myeloma. Hematol Oncol (13th International Conference on Malignant Lymphoma) 33:1-365(Abstr 80), 2015. e-Pub 2015.
128. Ahmed MA, Chihara D, Vargas N, Ma L, Fayad LE, Oki Y, Hagemeister FB, Romaguera JE, Turturro F, Fowler N, Rodriguez MA, Samaniego F, Fanale MA, Nastoupil L, Wang M, Lee HJ, Kwak LW, Noorani M, Davis RE, Westin JR, Neelapu SS. Outcome of relapsed/refractory diffuse large B-cell lymphoma after second salvage therapy: MD Anderson experience. Hematol Oncol (13th International Conference on Malignant Lymphoma) 33:1-365(Abstr 375), 2015. e-Pub 2015.
129. Fowler N, Cheah C, Neelapu S, Nastoupil L, Turturro F, Hagemeister F, Kwak LW, Romaguera J, Fanale M, Fayad L, Claret L, Feng E, Davis RE, Samaniego F. Extended dosing lenalidomide with intensified rituximab in untreated indolent NHL. Hematol Oncol (13th International Conference on Malignant Lymphoma) 33:1-365(Abstr 192), 2015. e-Pub 2015.
130. Samaniego F, Mathur R, Sehgal L, Neelapu S. FGF Signaling supports mantle cell lymphoma survival in the presence of mesenchymal stromal cells. Hematol Oncol (13th International Conference on Malignant Lymphoma) 33:1-365(Abstr 167), 2015. e-Pub 2015.
131. Fowler N, Nastoupil L, Neelapu S, Turturro F, Hagemeister F, Kwak LW, Romaguera J, Fanale M, Fayad L, Forbes S, Khan J, Samaniego F, Cheah C. Lenalidomide and Obinutuzumab in previously treated indolent lymphoma, Results of a Phase I Dose Escalation Study. Hematol Oncol (13th International Conference on Malignant Lymphoma) 33:1-365(Abstr 342), 2015. e-Pub 2015.
132. Cheah C, Ahmed M, Davis R, Nastoupil L, Chihara D, Kwak LW, Fayad LE, Phansalkar K, Samaniego F, Neelapu SS, Fowler NH. Comparison of lenalidomide and rituximab with chemoimmunotherapy in patients with untreated grades 1-2 follicular lymphoma treated at the MD Anderson Cancer Center. Hematol Oncol (13th International Conference on Malignant Lymphoma) 33:1-365(Abstr 191), 2015. e-Pub 2015.
133. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros J, Fanale MA, Hagemeister FB, Fayad L, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler N, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of Hyper-CVAD with pegylated liposomal doxorubicin alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with newly diagnosed T- and NK-cell lymphoma (T/NKCL). J Clin Oncol (ASCO Annual Meeting 2015) 33(Suppl; Abstr 8538), 2015. e-Pub 2015.
134. Berdeja JG, Oki Y, Patel MR, Flinn I, Neelapu SS, Clancy MS, Viner J, Wang J, Younes A. Phase 1 first-in-human trial of oral CUDC-907, a dual inhibitor of PI3K and HDAC, in patients with refractory/relapsed lymphoma or multiple myeloma. J Clin Oncol (ASCO Annual Meeting 2015) 33(Suppl; Abstr 8537), 2015. e-Pub 2015.
135. Mathur R, Sehgal L, Berkova Z, Neelapu SS, Samaniego F. Inhibition of demethylase, JMJD3 sensitizes diffuse large B-cell lymphoma (DLBCL) to chemotherapy. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015. e-Pub 2015.
136. Sehgal L, Mathur R, Berkova Z, Khashab T, Wang X, Romaguera J, Rodriguez AE, Neelapu S, Samaniego F. Tumor microenvironment influences survival of mantle cell lymphoma-initiating cells through FGF/FGFR1 signaling. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015. e-Pub 2015.
137. Yang Q, Chen LS, Neelapu SS, Gandhi V. Idelalisib impacts cell growth through inhibiting translation regulatory machineries in mantle cell lymphoma. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015. e-Pub 2015.
138. Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, Wallace M, Klinger M, Carlton V, Kong KA, Faham M, Younes A. Sequence Level Analysis of Hodgkin Lymphoma Clonotypes Detected in Peripheral Blood Using a Next-Generation Sequencing Approach. Blood (ASH 56th Annual Meeting) 124(21), 2014. e-Pub 2014.
139. Ishizawa J, Kojima K, Chachad D, Ruvolo PP, Ruvolo VR, Jacamo R, Dilip A, Mu H, Zeng Z, Matre P, Allen JE, Neelapu SS, McDonnell TJ, Miranda RN, Kwak LW, Kantarjian HM, Konopleva M, Davis RE, Andreeff M. ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition. Blood (ASH 56th Annual Meeting) 124(21), 2014. e-Pub 2014.
140. Oki Y, Fanale MA, Romagerua JE, Fayad L, Fowler N, Copeland ARM, Samaniego F, Kwak LW, Neelapu SS, Wang M, Feng L, Younes A. Phase II Study of an AKT Inhibitor MK2206 in Patients with Relapsed or Refractory Lymphoma. Blood (ASH 56th Annual Meeting) 124(21), 2014. e-Pub 2014.
141. Samaniego F, Sehgal L, Braun FK, Berkova Z, Romaguera JE, Wang M, Rodriguez MA, Neelapu SS, Mathur R. Molecular Signatures of Tumor-Initiating Cells Unveil Wnt Pathway As a Therapeutic Target in Mantle Cell Lymphoma. Blood (ASH 56th Annual Meeting) 124(21), 2014. e-Pub 2014.
142. Lee ST, Percivalle E, Cheng X, Lizee G, Fowler N, Davis RE, Neelapu SS. Intratumoral and Peripheral Blood T Cells Recognize Mutated Neo-Antigens in Follicular Lymphoma. Blood (ASH 56th Annual Meeting) 124(21), 2014. e-Pub 2014.
143. Gopisetty A, Foglietta M, Zhang M, Wang Z, Fowler N, Davis RE, Neelapu SS. Prosurvival and Chemoprotective Effects of Tumor-Associated Macrophages Reversed By Anti-CSF-1R Monoclonal Antibody in B-Cell Lymphomas. Blood (ASH 56th Annual Meeting) 124(21), 2014. e-Pub 2014.
144. Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez MA, Samaniego F, Fowler N, Oki Y, Turturro F, Westin JR, Kwak LW, Dabaja BS, Feng L, Davis RE, Neelapu SS. Antibiotic Therapy of H. Pylori Negative Gastric MALT Lymphoma. Blood (ASH 56th Annual Meeting) 124(21), 2014. e-Pub 2014.
145. Phansalkar K, Ahmed MA, Fowler N, Ma L, Noorani M, Lee ST, Feng L, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale MA, Wang M, Oki Y, Turturro F, Westin JR, Nastoupil LJ, Kwak LW, Davis RE, Neelapu SS. R-Bendamustine Vs R-CHOP As Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis. Proceedings of 56th American Society of Hematology Annual Meeting 124(21), 2014. e-Pub 2014.
146. Ahmed MA, Fowler N, Ma L, Noorani M, Phansalkar K, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin JR, Kwak LW, Nastoupil LJ, Cheah C, Feng L, Rohren EM, Davis RE, Neelapu SS. SUVmax on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Threapy. Blood (ASH 56th Annual Meeting) 124(21), 2014. e-Pub 2014.
147. Janku F, Oki Y, Falchook GS, Subbiah V, Naing A, Bravo VMV, Hong DS, Westin JR, Nunez C, Fayad L, Neelapu SS, Kwak LW, Shpall EJ, Wheler JJ, Barnes T, Liang WS, Salhia B, Meric-Bernstam F, Kurzrock R, Fanale MA. Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. Proceedings of the 50th American Society of Clinical Oncology Annual Meeting, 2014. e-Pub 2014.
148. Nastoupil LJ, Neelapu SS, Samaniego F, Hagemeister FB, Romaguera JE, Kwak LW, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Mclaughlin P, Fowler, NH. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. Proceedings of the 50th American Society of Clinical Oncology Annual Meeting, 2014. e-Pub 2014.
149. Thomas SK, Melendez AG, Feng L, Wang M, Neelapu SS, Shah JJ, Orlowski RZ, Weber DM. Phase I trial of pomalidomide (P) in patients (pts) with relapsed and/or refractory (R/R) Waldenström's macroglobulinemia (WM). Proceedings of the 50th American Society of Clinical Oncology Annual Meeting, 2014. e-Pub 2014.
150. Yang Q, Chen LS, Neelapu SS, Gandhi V. The PI3Kδ inhibitor, idelalisib, inhibits transcription and translation through PI3K/Akt pathway in mantle cell lymphoma. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research:4529, 2014. e-Pub 2014.
151. Sarkar AK, Balakrishnan K, Ayres M, Neelapu SS, Gandhi V. Essential role of ataxia telangiectasia in mitochondrial autophagy in mantle cell lymphoma. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research:313, 2014. e-Pub 2014.
152. Oki Y, Noorani M, Davis RE, Neelapu SS, Rodriguez A, Hagemeister FB, Fowler N, Wang M, Fanale MA, Samaniego F, Dabaja BS, Pinnix C, Kwak LW, Romaguera JE, Khouri I, Westin JR, Fayad LE. Double Hit Lymphoma: M.D. Anderson Experience. Blood (ASH Annual Meeting Abstracts) 122(1776), 2013. e-Pub 2013.
153. Oki Y, Neelapu SS, Fanake MA, Kwak LW, Fayad LE, Rodriguez A, Wallace M, Carlton V, Kong K, Faham M, Younes A. Detection Of Classical Hodgkin Lymphoma In Peripheral Blood Using High-Throughput Sequencing Assay. Blood (ASH Annual Meeting Abstracts) 122(627), 2013. e-Pub 2013.
154. Strati P, Romaguera JE, Kwak LW, Hagemeister FB, Rodriguez MA, Oki Y, Westin JR, Turturro F, Overman MJ, Neelapu SS, Fowler N, Fayad L. Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). Blood (ASH Annual Meeting Abstracts) 122(3028), 2013. e-Pub 2013.
155. Sehgal L, Braun FK, Mathur R, Neelapu S, Kwak LW, Berkova Z, Samaniego F. FAS-AS1 Intronic Lncrna and Ibrutinib Negatively Regulate Soluble Fas Production and Sensitize B-Cell Lymphomas To Fas-Mediated Apoptosis. Blood (ASH Annual Meeting Abstracts) 122(5051), 2013. e-Pub 2013.
156. Anderlini P, Saliba RM, Ledesma C, Chancoco CM, Alexander T, Amin A, Hosing CM, Khouri I, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Oki Y, Romaguera JE, Neelapu S, Younes A, Champlin RE. Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). Blood (ASH Annual Meeting Abstracts) 122(410), 2013. e-Pub 2013.
157. Havranek O, Westin JR, Zhang M, Rawal S, Kwak LW, Neelapu SS, Davis RE. Integrated Analysis Of Genomic and Gene Expression Profiles In Follicular Lymphoma Reveals Subsets and Driver Genes Of Potential Microenvironmental Importance. Blood (ASH Annual Meeting Abstracts) 122(2487), 2013. e-Pub 2013.
158. Ishizawa J, Kojima K, Dilip A, Ruvolo VR, Carter BZ, Allen JE, Neelapu SS, McDonnell TJ, Talekar MK, El-Deiry WS, Kwak LW, Andreeff M. ONC201 Exerts p53-Independent Cytotoxicity Through TRAIL and DR5 Induction In Mantle Cell Lymphomas. Blood (ASH Annual Meeting Abstracts) 122(3822), 2013. e-Pub 2013.
159. Oki Y, Fanale MA, Westin JR, Fowler N, Neelapu SS, Hagemeister FB, Rodriguez MA, Younes A. A Phase I Study Of Panobinostat In Combination With ICE (Ifosfamide, Carboplatin and Etoposide) In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (cHL). Blood (ASH Annual Meeting Abstracts) 122(252), 2013. e-Pub 2013.
160. Samaniego F, Romaguera JE, Fowler N, Fanale MA, Shah JJ, McLaughlin P, Pro B, Selvaraj V, Braun FK, Mathur R, Feng, L, Neelapu S, Kwak LW. A Single Center Phase II Trial Of 90yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease. Blood (ASH Annual Meeting Abstracts) 122(3039), 2013. e-Pub 2013.
161. Westin R, Chu F, Fayad L, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, Davis RE, Neelapu SS. Phase II Safety and Efficacy Study of Pidilizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Hematol Oncol 31(Suppl. I):150, 2013. e-Pub 2013.
162. Samaniego F, Romaguera J, Fowler N, Fanale M, Pro B, Shah J, McLaughlin P, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu S, Kwak L. A single center phase II trial of 90Yttrium-ibritumomab-tiuxetan produces high response rates as first-line therapy for early stage B-cell indolent lymphoma including bulky disease. Hematol Oncol 31(Suppl. I):163, 2013. e-Pub 2013.
163. Yang Q, Chen LS, Neelapu SS, Lanutti BJ, Gandhi V. PI3Kδ inhibitor, GS-1101, impacts transcription and translation in mantle cell lymphoma. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013, 2013. e-Pub 2013.
164. Sarker A, Chen J, Neelapu SS, Balakrishnan K, Gandhi V. L14R8, a Pac derivative, induces casapase-3 mediated apoptosis in mantle cell lymphoma. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013, 2013. e-Pub 2013.
165. Oki Y, Faham M, Carlton V, Neelapu SS, Younes A. Detection of Diffuse Large B-Cell Lymphoma. Blood (ASH Annual Meeting Abstracts), 2012. e-Pub 2012.
166. Oki Y, Chuang H, Chasen B, Pan T, Fanale MA, Dabaja BS, Fowler NH, Romaguera JEE, Fayad LE, Hagemeister FB, Rodriguez A, Neelapu SS, Samaniego F, Kwak LW, Younes A. The Prognostic Value of Interim PET Scan in Patients with Classical Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts), 2012. e-Pub 2012.
167. Westin JR, Chu F, Fayad LE, Kwak LW, Fowler NH, Romaguera JE, Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, Neelapu S. Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts), 2012. e-Pub 2012.
168. Chu F, Westin JR, Zhang M, Feng L, Baladandayuthapani V, Wang Z, Allen R, Wallace M, Vence L, Radvanyi L, Kwak LW, Rotem-Yehudar R, Davis RE, Neelapu SS. Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma Treated with CT-011, a Humanized Anti-PD-1 Monoclonal Antibody. Blood (ASH Annual Meeting Abstracts), 2012. e-Pub 2012.
169. Takahashi K, Sivina M, Oki Y, Fayad LE, Neelapu SS, Kwak LW, Xiao L, Huang X, Fu K, Chan WC, Vose JM, Kantarjian HM, Keating M, Burger JA. Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma. Blood (ASH Annual Meeting Abstracts), 2012. e-Pub 2012.
170. Percivalle E, Chu F, Davis RE, Neelapu SS. Effector and Requlatory T Cell Subsets in Follicular Lymphoma Tumors: Implications of Pathogenesis and Prognosis. Blood (ASH Annual Meeting Abstracts), 2012. e-Pub 2012.
171. Rawal S, Fowler N, Zhang M, Wang Z, Muzzafar T, Harun N, Baladandayuthapani V, Sharma R, Delgado D, Wallace M, Heise C, Lacerte LC, Samaniego F, Davis RE, Neelapu SS. Activation of T and NK Cells Following Lenalidomide Therapy in Patients with Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts), 2012. e-Pub 2012.
172. Oki Y, Westin JR, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaneigo F, Fayad L. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. Blood (ASH Annual Meeting Abstracts), 2012. e-Pub 2012.
173. Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LWRomaguera JE, Fanale MA, Fayad LE, Orlowski RZ, Wang M, Turturro F, Oki Y, Lacerte LC, Samaniego F. Lenalidomide and Rituximab for Untreated Indolent Lymphoma:Final Results of a Phase II Study. Blood (ASH Annual Meeting Abstracts), 2012. e-Pub 2012.
174. Samanieg F, Wise JF, Tao RH, Z Haifeng Z, Ao X, Chen Z, Zhuang W, Braun FK, Mathur R, Romaguera JE, Fayad L, Wang M, McLaughlin P, McDonnell TJ, Patel KP, Neelapu SS, Kwak LW, Berkova Z. Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin. Blood (ASH Annual Meeting Abstracts), 2012. e-Pub 2012.
175. Dunleavy K, Neelapu SS, Kwak LW, Grant C, Santos CF, Popa MA, White T, Miller B, Jaffe ES, Steinberg SM, Wilson WH. Association of idiotype vaccine-induced T-cell response with improved survival and time-to-next treatment (TTNT) in untreated mantle cell lymphoma (MCL). J Clin Oncol 30, 2012 (suppl; abstr 2528), 2012. e-Pub 2012.
176. Takahashi K, Sivina M, Xiao L, Oki Y, Fayad L, Neelapu S, Kwak LW, Kantarjian H, Keating MJ, Huang X, Burger JA. Serum CCL3 and CCL4 levels function as novel prognostic markers in Diffuse Large B Cell Lymphoma. The European Hematology Association Annual Meeting, 2012. e-Pub 2012.
177. Wang M, Fowler N, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M, Younes A, Zhang L, Champlin R, Kwak L, Feng L, Byrne C, Bell N, Zeldis J, Romaguera J, Fayad L. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in a cohort of patient with DLCL: A completed phase II clinical trial. The European Hematology Association Annual Meeting, 2012. e-Pub 2012.
178. Vadhan-Raj S, Spasojevic I, Zhou X, Romaguera J, Fanale M, Fayad L, Fowler N, Huen A, Hagemeister FB, Rodriguez MA, Neelapy SS, Samaniego F, Younes A, Kwak LW. Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study. Blood (ASH Annual Meeting Abstracts), 2011. e-Pub 2011.
179. Fowler N, Neelapu SS, Fanale MA, Rodriguez MA, Pro B, Hagemeister FB, Younes A, Shah JJ, Kwak LW, Rodriguez D, McLaughlin P. Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts), 2011. e-Pub 2011.
180. Rawal S, Park HJ, Chu F, Zhang M, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Davis RE, Neelapu SS. Role of IL-4 in Inducing Immunosuppressive Tumor Microenvironment in Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts), 2011. e-Pub 2011.
181. Grant C, Neelapu SS, Kwak LW, Dunleavy K, White T, Miller B, Jaffe E, Steinberg S, Bird BH, Wilson WH. 10. Eleven-Year Follow-up of Idiotype Vaccine and DA-EPOCH-Rituximab in Untreated Mantle Cell Lymphoma: Correlation of Survival with Idiotype Immune Response. Blood (ASH Annual Meeting Abstracts), 2011. e-Pub 2011.
182. Chu F, Ma W, Yamazaki T, Foglietta M, Nattama D, Rawal S, Wang Z, Goa Y, Orozco N, Vence L, Radvanyi L, Dong C, Davis RE, Neelapu S. PD-1+ T Cell Subsets in Follicular Lymphoma Tumor Microenvironment and Their Implications for Prognosis and Therapy. Blood (ASH Annual Meeting Abstracts), 2011. e-Pub 2011.
183. Kannan S, Chu F, Rawal S, Foglietta M, Delgado D, Neelapu SS. Cross-Talk Between Tumor B Cells, Follicular Dendritic Cells, and Follicular Helper T Cells: Implications for Follicular Lymphoma Pathogenesis and Therapy. Blood (ASH Annual Meeting Abstracts), 2011. e-Pub 2011.
184. Younes A, Copeland A, Fanale MA, Fayad L, Romaguera JE, Kwak LW, Neelapy SS, Hagemeister F, Pro B, de Castro Faria S, Ji Y, Berry D, Buglio D, Medeiros LJ. Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts), 2011. e-Pub 2011.
185. Weng J, Rawal S, Park HJ, Sharma R, Neelapu S. TCL1: A Shared Tumor-Associated Antigen for Immunotherapy Against B-Cell Lymphomas. Blood (Ash Annual Meeting Abstracts), 2011. e-Pub 2011.
186. Khouri IF, Saliba RM, Valverde R, Samuels B, Korbling M, Alousi AM, Anderlini P, Bashir Q, De Lima M, Hosing C, Kebriaei P, Nieto Y, Popat UR, Qazilbash M, Neelapu S, Fowler N, Samaniego F, Wang L, Champlin R, Macapinlac HA. Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results. Blood (ASH Annual Meeting Abstracts), 2011. e-Pub 2011.
187. Buglio D, Lemoine M, Estrella J, Neelapu SS, Davis RE, Doyle L, Little R, Berry D, Younes A. The Allosteric AKT Inhibitor MK-2206 Demonstrates Potent Antiproliferative Activity in Lymphoma Cells and Synergizes with the HDAC Inhibitor Vorinostat. Blood (ASH Annual Meeting Abstracts, 2011. e-Pub 2011.
188. Wang L, Qian J, Lu Y, Li H, Hong S, Bao H, He D, Liu Z, Zheng Y, He J, Lan Y, Li Y, Neelapy S, Yang J, Wang M, Zhen C, Yi Q. Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells. Blood (ASH Annual Meeting Abstracts), 2011. e-Pub 2011.
189. Samaniego F, Hagemeister F, Mclaughlin P, Kwak L, Romaguera J, Fanale M, Neelapu SS, Fayad L, Orlowski R, Wang M, Lacerte L, Fowler N. High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. J Clin Oncol ASCO Annual Meeting 2011 29(8030), 2011. e-Pub 2011.
190. Rodriguez MA, Durand J, Astrow AB, Bury MJ, Fanale MA, Hagemeister F, Huang X, McLaughlin P, Neelapu SS, Pro B, Kwak L, Fayad L, Romaguera J, Younes A, Fisch M. Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for patients older than age 60 with untreated diffuse large B-cell lymphoma (DLBCL). J Clin Oncol ASCO Annual Meeting 2011 29(8053), 2011. e-Pub 2011.
191. Fowler N, Mclaughlin P, Fisch M, Dakhil S, Bury M, Fayad L, Shah J, Neelapu S, Romaguera J, Rodriguez D, Ayala A, Kwak L. Rituximab plus sargramostim for the treatment of. Annals of Oncology 11th International Conference on Malignant Lymphoma 22(Suppl 4), 2011. e-Pub 2011.
192. Fowler N, Hagemeister F, Mclaughlin P, Kwak L, Romaguera J, Fanale M, Neelapu S, Fayad L, Orlowski R, Wang M, Pro B, Lacerte L, Samaniego F. Lenalidomide plus rituximab is a highly effective and well-tolerated biologic therapy in untreated indolent b cell non-hodgkins lymphoma. Annals of Oncology 11th International Conference on Malignant Lymphoma 22(Suppl 4), 2011. e-Pub 2011.
193. Wang M, Fayad L, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M, Younes A, Cabanillas F, Zhang L, Champlin R, Kwak L, Feng L, Bell N, Zeldis J, Romaguera J. Oral lenalidomide plus 4 doses of rituximab. Annals of Oncology 11th International Conference on Malignant Lymphoma 22(Suppl 4), 2011. e-Pub 2011.
194. Voo K S, Foglietta M, Bover L, Kwak L, Jun-Liu Y, Neelapu SS. Reversing the suppressive effects of regulatory T cells by targeting toll-like receptors and OX40 in human follicular lymphoma. American Association of Immunology Annual Meeting 2011, 2011. e-Pub 2011.
195. Yang Q, Medeiros J, Neelapu SS, Chen L, Gandhi V. Targeting Pim Kinases inhibition by SGI-1776 in Mantle Cell Lymphoma. American Association for Cancer Research Annual Meeting 2011, 2011. e-Pub 2011.
196. Zhang L, Yang J, Qian J, Neelapu S, Kwak L, Wang M, Yi Q. Role of Microenvironment In Mantle Cell Lymphoma: IL-6 as An Important Survival Factor for Tumor Cells. Blood (ASH Annual Meeting Abstracts) 116:3929, 2010. e-Pub 2010.
197. Fanale MA, Lai CM, McLaughlin P, Romaguera J, Fayad L, Hagemeister F, Samaniego F, Rodriguez MA, Neelapu SS, Shah JJ, Kwak L, Dong W, Reed V, Dabaja BS, Popat U, Younes A. Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP. Blood (ASH Annual Meeting Abstracts) 116:2812, 2010. e-Pub 2010.
198. Weng J, Cha SC, Matsueda S, Neelapu S, Kwak LW. Targeting Multiple Myeloma with Human Ig Light Chain Specific Cytotoxic T Lymphocytes. Blood (ASH Annual Meeting Abstracts) 116:3018, 2010. e-Pub 2010.
199. Cha SC, Qin H, Kannan S, Rawal S, Wu W, Ong J, Wei J, Kwak B, Kim S, Popescu MS, Paick DS, Hong S, Davis RE, Kwak LW, Neelapu SS. Non-Stereotypic Follicular Lymphoma B-Cell Receptors Recognize Vimentin as a Shared Autoantigen. Blood (ASH Annual Meeting Abstracts) 116:139, 2010. e-Pub 2010.
200. Schuster SJ, Santos CF, Neelapu SS, Berry DA, Popa MA, McCord AM, Chong EA, Kwak L. Vaccination with IgM but Not IgG Idiotype Prolongs Remission Duration In Follicular Lymphoma Patients. Blood (ASH Annual Meeting Abstracts) 116:429, 2010. e-Pub 2010.
201. Buglio D, Palakurti S, Vega F, Neelapu SS, Berry D, Ji Y, Byth K, Younes A. Inhibition of Tak-1 by AZ-Tak1 Impairs NF-B Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma. Blood (ASH Annual Meeting Abstracts) 116:2852, 2010. e-Pub 2010.
202. Westin JR, Chu F, Foglietta M, Rotem-Yehudar R, Neelapu SS. Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. J Clin Oncol 28:15s, 2010 (suppl; abstr TPS305), 2010. e-Pub 2010.
203. Fowler NH, McLaughlin P, Hagemeister FB, Kwak LW, Fanale MA, Neelapu SS, Fayad L, Orlowski RZ, Wang M, Samaniego F. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 28:15s, 2010 (suppl; abstr 8036), 2010. e-Pub 2010.
204. Popa-Mckiver MA, McCord AM, Neelapu SS, Santos CF. FC-gamma receptor IIIA (FCGR3A) polymorphism and DFS in follicular lymphoma patients after idiotype vaccination in first remission. J Clin Oncol 28, 2010 (suppl; abstr e13125), 2010. e-Pub 2010.
205. Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, Caraway N, Neelapu SS, Kwak LW, Simmons P, McCarty N. Prospective isolation of clonogenic mantle cell lymphoma initiating cells. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research, 2010. e-Pub 2010.
206. Rawal S, Park HJ, Foglietta M, Nattamai D, Chou T, Kannan S, Neelapu SS. TH2 cells interact with tumor cells to facilitate recruitment of regulatory T cells into the tumor microenvironment in human B-cell lymphomas. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research, 2010. e-Pub 2010.
207. Wang L, Fayad L, Hagemeister FB, Neelapu S, Samaniego F, McLaughlin P, Samuels B, Yi Q, Pro B, Fanale F, Shah J, Younes A, Bell N, Knight R, Zeldis JB, Cabanillas F, Kwak L, Romaguera J. A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 114(22):1064, 2009. e-Pub 2009.
208. Qian J, Hong S, Zhang L, Zheng Y, Li H, Yang J, Neelapu S, Yi Q. Targeting DKK1 for the Immunotherapy of B-Cell Lymphomas. Blood (ASH Annua Meeting Abstracts) 114(22):192, 2009. e-Pub 2009.
209. Chu F, Foglietta M, Qin H, Sharma R, Yi Q, Rodionov G, Rotem-Yehudar R, Neelapu S. In Vitro and In Vivo Effects of CT-011, a Humanized Anti–PD-1 Monoclonal Antibody, in Combination with Rituximab against Human B-Cell Lymphomas. Blood (ASH Annual Meeting Abstracts) 114(22):302, 2009. e-Pub 2009.
210. Westin JR, Thompson MA, Cataldo VD, Toth BB, Sanjorjo P, Bourgeois S, Jimenez C, Murphy WA, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister FB. Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. Blood (ASH Annual Meeting Abstracts) 114(22):1508, 2009. e-Pub 2009.
211. Foglietta M, Neelapu S, Foweler DH, Steinberg SM, Kwak LW, Bishop MR. Analysis of Antigen-Specific T-Cell Responses and Regulatory T Cells Following Sibling Donor Immunization with Patient-Derived Idiotype Vaccine Prior to Non-Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 114(22):887, 2009. e-Pub 2009.
212. Fowler N, McLaughlin P, Hagemeister FB, Kwak L, Fanale M, Neelapu S, Fayad L, Pro B, Sergent C, White SRS, Samaniego F. A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma. Blood (ASH Annual Meeting Abstracts) 114(22):683, 2009. e-Pub 2009.
213. Jamshed S, Fowler D, Neelapu S, Dean RM, Steinberg SMm Snow K, Odom J, Gress RE, Bishop M. EPOCH-F: A salvage regimen for multiple myeloma prior to reduced intensity allogeneic hematopoetic stem cell transplantation. ASCO Meeting 27, 2009. e-Pub 2009.
214. Khouri IF, Harrell R, Valverde R, Korbling M, Manshouri T, Samuels B, Maadani F, Okoroji GJ, Jr B, Amin A, Anderlini A, De Lima M, Giralt S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, Stachowiak AM, Erwin E, Fayad L, Pro B, Fowler N, McLaughlin P, Neelapu S, Younes A, Champlin R, Podoloff D. Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin’s Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies. Blood (ASH Annual Meeting Abstracts) 114(22):357, 2009. e-Pub 2009.
215. Bishop MR, Kwak LW, Fowler DH, Giralt S, Steinberg SM, Bryant K, Neelapu SS. Sibling Donor immunization with patient-derived ID-KL vaccine prior to reduced -intensity allogeneic hematopoetic cell transplantation for multiple myeloma. ASCO Meeting 27, 2009. e-Pub 2009.
216. Schuster SJ, Neelapu SS, Gause BL, Muggia FM, Gockerman JP, Sotomaryor EM, Winter JN, Flowers CR, Stergio AM, Kwak LW. Idiotype vaccine therapy (Biovax ID) in follicular lymphoma in first complete remission: Phase III clinical trial results. ASCO Meeting 27(2), 2009. e-Pub 2009.
217. Rawal S, Park HJ, Foglietta M, Nattamai D, Kwak LW, Neelapu SS. Active recruitment of regulatory T cells into follicular lymphoma tumor microenvironment. Proceedings of the 100th Annual Meeting of AACR, 2009. e-Pub 2009.
218. Kannan S, Neelapu SS. Meta-analysis of multiple follicular lymphoma GEO datasets reveals the significance of tumor microenvironment in disease progression. Proceedings of the 100th Annual Meeting of AACR, 2009. e-Pub 2009.
219. Cha SC, Qin H, Wu W, Kannan S, Ong J, Wei J, Kwak B, Kim SJ, Gold D, Kwak LW, Neelapu SS. Follicular lymphoma B-cell receptors recognize vimentin: Implications for lymphomagenesis. Proceedings of the 100th Annual Meeting of AACR, 2009. e-Pub 2009.
220. Freedman AS, Neelapu S, Nichols CR, Robertson M, Djulbegovic B, Winter JN, Gold D, Bender J, Stewart M, Ghalie RG, Hamlin PA. A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts) 112, 2008. e-Pub 2008.
221. Lee ST, Park KU, Nattamai D, Cha SC, Qin H, Kwak LW, Neelapu SS. Activation of follicular lymphoma tumor cells with TLR9 agonist and CD40 ligand facilitates rapid and efficient generation of lymphoma-specific T cells. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, 2008. e-Pub 2008.
222. Samaniego F, Fanale M, Pro B, Hagemeister F, McLaughlin P, Romaguera J, Neelapu S, Rodriguez A, Fayad L, Younes A, Kwak L. Pentostatin combined with Cyclophosphamide, and Rituximab (PCR) achieve high response rates in indolent B-cell lymphoma. 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. e-Pub 2008.
223. Wang M, Fayad L, Hagemeister F, Neelapu S, Samuels B, Samaniego F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera J. Lenalidomide in combination with rituximab is effective with manageable toxicity in a Phase I/II study in relapsed/refractory mantle cell lymphoma. 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. e-Pub 2008.
224. Neelapu SS, Nattamai D, Foglietta M, Kwak LW. Blockade of PD-1/PD-ligand pathway restores function of intratumoral effector T cells in follicular lymphoma. 10th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2008. e-Pub 2008.
225. Rawal S, Cha SC, Qin H, Kwak LW, Neelapu SS. Stat6 is constitutively activated in human follicular lymphoma. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, 2008. e-Pub 2008.
226. Wang M, Zhang L, Fayad L, Hagemeister F, Neelapu S, Samaniego F, Pro B, Younes A, Miller S, Knight RD, Zeldis JB, Yi Q, Romaguera J. Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 112, 2008. e-Pub 2008.
227. McLaughlin P, Neelapu S, Fanale M, Rodriguez M, Ayala A, Pro B, Hagemeister FB, Younes A, Anas N, Fowler N, Hess M, Kwak LW. R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts) 112, 2008. e-Pub 2008.
228. Samaniego F, Fanale M, Pro B, Hagemeister FB, McLaughlin P, Romaguera J, Neelapu S, Rodriguez MA, Fayad L, Younes A, Kwak LW. Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression. Blood (ASH Annual Meeting Abstracts) 112, 2008. e-Pub 2008.
229. Foglietta M, Delgado D, Nattamai D, Kwak LW, Neelapu S. CD4+Foxp3+ Regulatory T Cells Persist in High Numbers in Peripheral Blood after Induction of Clinical Remission with Standard Chemotherapy and Suppress Tumor-Specific Effector T Cells in Patients with Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts) 112:309, 2008. e-Pub 2008.
230. Cataldo VE, Thompson MA, Toth BB, Sanjorjo P, Bekele P, Jimenez C, Murphy WA, Huen AO, Arbuckle RB, Fanale MA, Fayad LE, Fowler N, Kwak LW, McLaughlin P, Neelapu SS, Pro B, Rodriguez A, Shah J, Hagemeister FB. Bone Loss in Patients with Previously Untreated Lymphoma: The Effect of Periodontal Disease on the Use of Zoledronic Acid. Blood (ASH Annual Meeting Abstracts) 112, 2008. e-Pub 2008.
231. Jamshed S, Fowler D, Neelapu S, Robert M, Dean RD, Steinberg SM, Odom J, Snow K, Gress RE, Bishop MR. EPOCH-F: A Novel Salvage Regimen for Multiple Myeloma Prior to Reduced-Intensity Allogeneic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts 112, 2008. e-Pub 2008.
232. Nastoupil L, Westin JR, Fowler NH, Fanale MA, Samaniego F, Oki Y, Dsouza L, Obi C, Cao JJ, Cheng X, MA MCJ, Zhiqiang W, Feng L, Zhou S, Davis RE, Neelapu SS. High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study. Blood (59th Annual Meeting), 2007. e-Pub 2007.
233. Younes A, Fanale M, Pro B, McLaughlin P, Neelapu SS, Fayad L, Wedgwood W, Dubay M, Martell RE. A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (Proceedings of the Annual ASCO Meeting-Part 1, 2007) 25(18S):8000, 2007. e-Pub 2007.
234. Fayad L, Pro B, Hagemeister F, Cabanillas F, Samaniego F, McLaughlin P, Wang M, Neelapu S, Kwak LW, Romaguera J, Rodriguez MA. R-HCVAD/R-MTX-ARAC is an effective regimen for untreated diffuse large B-cell lymphoma (DLBCL) with aggressive features in patients younger than 6t0 years. Blood 110:1285, 2007. e-Pub 2007.
235. Voo KS, Bover LDC, Neelapu SS, Kwak LW, Liu YF. OX40-ligand inhibits function of IL-10 producing intratumoral CDr+CD25+ regulatory T cells in human follicular B-cell lymphoma. J Immunol (Proceedings of the American Association of Immunologists Annual Meeting) 178:50:25, 2007. e-Pub 2007.
236. Wang M, Fayad L, Hagemeister F, Neelapu S, Samuels B, Samaniego F, Pro B, Yi Q, Bell N, Byrne C Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera J. Lenalidomide (Len) in combination with rituximab (R) demonstrated early evidence of efficacy in a phase I/II study in relapsed/refractory mantle cell lymphoma (MCL). Blood 110:2562, 2007. e-Pub 2007.
237. Wang M, Fayad L, Hagemeister F, Neelapu SS, Bell N, Byrne C, Knight R, Zeldis J, Kwak L, Romaguera J. A phase I/II study of lenalidomide ( Len) in combination with rituximab in ( R) relapsed/refractory mantle cell lymphoma (MCL). J Clin Oncol (Proceedings, Annual ASCO Meeting-P-Part 1, 2007) 25(18S):8030, 2007. e-Pub 2007.
238. Nattamai D, Neelapu SS. PD-1 expression is markedly upregulated on intratumoral CD4+ and CD8+ T cells in follicular lymphoma and is associated with T-cell exhaustion. Blood 110:2749, 2007. e-Pub 2007.
239. Stergiou AM, Neelapu SS, Cascino R, Jaffe MA, Kwak LW. BiovaxID vaccine therapy of follicular lymphoma in first remission: Phase III blinded safety update. Blood 110:4500, 2007. e-Pub 2007.
240. Younes A, Pro B, Fanale M McLaughlin P, Neelapu S, Fayad L, Wedgewood A, Buglio D, Patterson T, Dubay M, Li Z, Martelli RE, Ward R, Bociek RG. Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma and is associated with T-cell exhaustion. Blood 110:2749, 2007. e-Pub 2007.
241. Wang M, Oki, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu SS, Podoloff D, Samuels B, Loyer E, Zhou Y, Younes A. Phase II study of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) in patients with relapsed and refractory mantle cell lymphoma (MCL). Proceedings of the 48th ASH Annual Meeting, 2006. e-Pub 2006.
242. Freedman AS, Hamlin PA, Neelapu SS, Nichols C, Robertson M, Bergier G, Winter JN, Polikoff J, Lin T, Pohlman B, Esquiel V, Melink T, Bender J. Phase III trial of active immunotherapy (Favld, Id/KLH) following rituximab induction therapy: clinical responses in patients (pts) with follicular non-Hodgkin's lymphoma (NHL).l. Proceedings of the 48th ASH Annual Meeting, 2006. e-Pub 2006.
243. Samaniego F, Fayad LE, Pro B, McLaughlin P, Rodriguez MA, Hagemeister FB, Fanale M, Neelapu SS, Younes A, Kwak LW. Pentostatin combined with cyclophosphamide and rituximab induces high response rates in patients with untreated indolent B-cell lymphoma. Proceedings of the 48th ASH Annual Meeting, 2006. e-Pub 2006.
244. Younes A, Fayad LE, Goy A, McLaughlin P, Pro B, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Kwak L, Neelapu S, Medeiros J, Wedgebood A, Fanale M. Results of rituximab plus ABVD in 65 newly diagnosed patients with classical Hodgkin's lymphoma: Improvement of event free survival (EFS) in all international prognostic score (IPS) groups. Proceedings of the 48th ASH Annual Meeting, 2006. e-Pub 2006.
245. Lee ST, Liu S Sukhumalchandra P, Molldrem J, Hwu P, Liu YJ, Kwak LW, Lizee G, Neelapu SS. A novel strategy for generation of human tumor-specific T-cell clones for adoptive transfer. Proceedings of the 48th ASH Annual Meeting, 2006. e-Pub 2006.
246. Neelapu SS, Lee ST, Wang YH, Sukhumalchandra P, Molldrem J, Weider E, Radvanyi L, Hui P Liu YJ, Kwak LW. A novel strategy for efficient cloning of human tumor-specific T cells. Proceedings of the American Association of Immunologists Annual Meeting, Boston, MA, 2006. e-Pub 2006.
247. Martin-Orozco N, Neelapu SS, Lee ST, Wang Y, Ito T, Molldrem J, Liu YJ, Dong C, Kwak L. T-cell co-inhibitory molecules and the response to human B-cell malignancies. Proceedings of the American Association of Immunologists Annual Meeting, Boston, MA, 2006. e-Pub 2006.
248. Ishiyama K, Kondo Y, Weider E, Lu S Martin-Orozco N, Dong C, Neelapu SS, Hwu P, Liu YJ, Kwak L, Molldrem J. High avidity PD-1 cyclin E-specific CTL contribute to leukemia remission and may be induced by epitope spread. Proceedings of the American Association of Immunologists Annual Meeting, Boston, MA, 2006. e-Pub 2006.
249. Gause BL, Neelapu SS, Cohen CM, Katz LM, Watson T, Stergiou AM, Kwak LW. Idiotype vaccine therapy of follicular lymphoma in first remission:Association of t(14;18) and disease-free survival in a phase II cohort. Proceedings of the 42nd ASCO Annual Meeting, 2006. e-Pub 2006.
250. Qin H, Sudhir KP, Cha SC, El-Bereir S, Neelapu SS, Roy K, Kwak LW. Development of a novel, injectable microparticle lymphoma DNA vaccine. Proceedings of the 97th AACR Annual Meeting, 2006. e-Pub 2006.
251. Younes A, Pro B, Rodriguez MA, Romaguera JE, McLaughlin P, Wang M, Hagemeister F, Dang NH, Neelapu S, Podoloff D. Activity of Yttrium90 (90Y) Ibritumomab Tiuxetan (Zevalin) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL). Proceedings of the 47th ASH Annual Meeting, 2005. e-Pub 2005.
252. Lee ST, Jiang YF, Cha SC, Qin H, Kwak LW, Neelapu SS. In vitro expansion of autologous follicular lymphoma-specific T cells for adoptive transfer. Proceedings of the 47th ASH Annual Meeting, 2005. e-Pub 2005.
253. Cha SC, Biragyn A, Ruffini PA, Qin H, Neelapu SS, Kwak LW. Cloning of B cell lymphoma-associated antigens using modified phage displayed expression cDNA library and immune patient sera. Proceedings of the 47th ASH Annual Meeting, 2005. e-Pub 2005.
254. Dang NH, McLaughlin P, Fayad L, Romagera J, Hagemeister F, Younes A, Neelapu S, Samaniego F, Jones D, Walker PL, Rodriguez MA, Kwak L, Pro B. Interim analyses of a phase II study of the combination of Denileuken Difitox (Ontak) and Rituximab for relapsed/refractory B-cell non-Hodgkin's lymphoma. Proceedings of the 47th ASH Annual Meeting, 2005. e-Pub 2005.
255. Romaguera JE, Fayad LE, Wang M, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez A, Younes A, Neelapu SS, Kwak L, Goy AH, Beasley V. High (95%) response rates in relapsed/refractory mantle cell lymphoma after R-HCVAD alternating with R-methotrexate/cytarabine (R-M-A). Proceedings of the 47th ASH Annual Meeting, 2005. e-Pub 2005.
256. Dang NH, Pro B, Hagemeister F, Samaniego F, Jones D, Rodriguez M, Goy A, Romaguera J, Walker PL, Younes A, Neelapu SS, Kwak L, Fayad L. Phase II study of Denileukin Difitox (Ontak) for relapsed/refractory non-Hodgkin's lymphoma. Proceedings of the 47th ASH Annual Meeting, 2005. e-Pub 2005.
257. Younes A, McLaughlin P, Fayad LE, Goy A, Romaguera JE, Pro B, Rodriguez MA, Samaniego F, Kwak L, Neelapu SS, Medeiros J. Six weekly doses of rituximab plus ABVD for newly diagnosed patients with advances stage classical Hodgkin's lymphoma: depletion of reactive B-cells from the microenvironment by Rituximab. Proceedings of the 47th ASH Annual Meeting, 2005. e-Pub 2005.
258. Bishop MR, Neelapu SS, Fowler DH, Krumlauf M, Gress R, Kwak LW. Preliminary Results of Sibling Donor Immunization with Patient-Derived Id-KLH Vaccine Prior to Reduced-Intensity Allogeneic Stem Cell Transplantation for Multiple Myeloma. Proceedings of the 46th American Society of Hematology Annual Meeting, 2004. e-Pub 2004.
259. Neelapu SS, Gause BL, Harvey L, Frye RA, Horton J, Robb RJ, Popescu MC, Kwak LW. Human autologous tumor-specific T-cell responses induced by liposome encapsulated lymphoma membrane proteins. Proceedings of the 46th American Society of Hematology Annual Meeting, 2004. e-Pub 2004.
260. Neelapu SS, Munshi NC, Jagannath S, Watson TM, Pennington R, Barlogie B, Kwak LW. Tumor Antigen Immunization of Sibling Stem Cell Transplant Donors in Multiple Myeloma. Proceedings of the 46th American Society of Hematology Annual Meeting, 2004. e-Pub 2004.
261. Neelapu SS, Wilson WH, Baskar S, White T, Frye R, Pennington R, Kwak LW. Induction of T cell responses by tumor antigen vaccination in mantle cell lymphoma following rituximab-based treatment. Proceedings of the 39th American Society of Clinical Oncology Annual Meeting, 2003. e-Pub 2003.
262. Wilson WH, Neelapu S, Rosenwald A, White T, Dunleavy K, Pittaluga S, Hakim F, Stetler-Stevenson M, Steinberg S, Jaffe ES, Gress R, Wright G, Staudt L, Janik J, Kwak L. Idiotype Vaccine and Dose-Adjusted EPOCH-Rituximab Treatment in Untreated Mantle Cell Lymphoma: Preliminary Report on Clinical Outcome and Analysis of Immune Response. Proceedings of the 45th American Society of Hematology Annual Meeting, 2003. e-Pub 2003.
263. Neelapu SS, Gause BL, Nikcevich DA, Schuster SJ, Winter J, Gockerman JP, Sotomayor E, Inghirami G, Muggia F, Watson TM, Snow S, Kubovic P, Ferraro M, Jaffe ES, Reynolds CW, Kwak LW. Vaccine therapy of follicular lymphoma in first remission: Long-term follow-up of phase II results and high rate of chemotherapy-induced complete remissions in a controlled, randomized phase III trial. Proceedings of the 45th American Society of Hematology Annual Meeting, 2003. e-Pub 2003.
264. Neelapu SS, Baskar S, Harvey L, Kwak LW. A novel strategy for efficient in vitro priming of T cells against a tumor antigen. . Proceedings of the 94th American Association for Cancer Research Annual Meeting,, 2003. e-Pub 2003.
265. Janik JE, Morris JC, Quinn C, Gao W, Waldmann TA, Wilson WH, Kwak LW, Pittaluga S, Neelapu S, Streicher H, Berzofsky JA, Dahut W, Arlen P, Gulley JL, Schlom J, Davis TA, Lowy I. A Pilot Study of MDX-010 after Vaccine Failure in Patients with Advanced Malignancy. Proceedings of the 45th American Society of Hematology Annual Meeting, 2003. e-Pub 2003.
266. Wilson WH, Neelapu S, White T, al E. Idiotype vaccine following EPOCH-Rituximab treatment in untreated mantle cell lymphoma. Blood 100:162a, 2002. e-Pub 2002.
267. Neelapu SS. Clinical and immunologic effects of a second generation lymphoma vaccine. Fellows Award for Research Excellence, NIH, 2002. e-Pub 2002.
268. Neelapu SS, Baskar S, Gause BL, Watson TM, Frye AR, Pennington R, Popescu MC, Robb R, Kwak LW. Clinical trial of a second generation lymphoma vaccine. Proceedings of the 93rd AACR Annual Meeting, 2002. e-Pub 2002.
269. Neelapu S, Baskar, Pennington R, Kwak LW. Clinical trial of a second generation lymphoma vaccine. Fellows and Young Investigators Retreat, NCI, NIH, Bethesda, MD, 2002. e-Pub 2002.
270. Neelapu SS, Baskar S, Kwak LW. Short term in vitro expansion enhances the detection of antigen-specific intracellular cytokine responses in myeloma patients vaccinated with tumor antigen. Third Annual Mayo Clinic Hematology/Oncology Fellows Poster Presentation, Mayo Clinic, Jacksonville, 2000. e-Pub 2000.

Letters to the Editor

1. Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol 204: e11-e16, 2024.
2. Li, X, Henderson, J, Gordon, MJ, Sheikh, IN, Nastoupil, L, Westin, JR, Flowers, CR, Ahmed, S, Wang, L, Neelapu, SS, Strati, P, Deng, Q, Green, M. A single-cell atlas of CD19 chimeric antigen receptor T cells. Cancer cell 41: 1835-1837, 2023.
3. Gribben J, Palomba ML, Patel AR, Nahas M, Neelapu SS. Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma. Blood Adv 7: 2494-2495, 2023.
4. Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Tejada FNH, Martin PL, Auletta J, Choi SW, Bajwa R, Garnes ND, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Author Correction: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18: 468, 2021.
5. Lee DW, Mead E, Santomasso BD, Turtle CJ, Grupp SA, Neelapu SS. Reply. Biol Blood Marrow Transplant 25: e211-e212, 2019.
6. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, Daver N, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15: 218, 2018.
7. Neelapu, Locke, Go. CAR T-Cell Therapy in Large B-Cell Lymphoma. N Engl J Med 378: 1065, 2018.
8. Schuster SJ, Neelapu SS, Santos CF, Popa-McKiver MA, McCord AM, Kwak LW. Idiotype Vaccination As Consolidation Therapy: Time for Integration Into Standard of Care for Follicular Lymphoma?. J Clin Oncol 29: 4845-6, 2011.